

Kimberly Page, PhD, MPH, MS
University of New Mexico Health Sciences Center
Curriculum Vitae

May 6, 2016

Office Address:

Department of Internal Medicine
 Division of Epidemiology, Biostatistics and Preventive Medicine
 1 University of New Mexico
 MSC10 5550
 Albuquerque, NM 87131-0001

Home Address:

648 Bosque Verde Ln. NW, Albuquerque, NM 87104

EDUCATIONAL HISTORY

1995-1998	Post-Doctoral Fellow	University of California San Francisco, San Francisco, CA	HIV Prevention
1992-1995	Ph.D.	University of California at Berkeley, Berkeley, CA	Epidemiology
1990-1992	MPH	University of California at Berkeley, Berkeley, CA	Epidemiology & Biostatistics
1978-1981	M.S.	North Texas State University, Denton, TX	Exercise Physiology
1973-1977	B.A.	University of California Santa Barbara, Santa Barbara, CA	Fine Arts

EMPLOYMENT HISTORY

2014-present	Professor and Chief, Division of Epidemiology, Biostatistics and Preventive Medicine	University of New Mexico Health Sciences Center, Albuquerque, NM
2010-2014	Professor in Residence, Department of Epidemiology and Biostatistics	University of California San Francisco
2008-2010	Associate Professor, Department of Epidemiology and Biostatistics	University of California San Francisco
2003-2007	Associate Professor, Department of Medicine	University of California San Francisco
1998-2002	Assistant Professor, Department of Medicine	University of California San Francisco

EMPLOYMENT HISTORY CONCURRENT

2016	Associate Director of Research - Project ECHO	University of New Mexico Health
------	---	---------------------------------

		Sciences Center
2015-present	Core Director: Biostatistics, Epidemiology and Research Design (BERD) Unit of the Research Expertise and Methods (REM) Core Clinical Translational Research Center	University of New Mexico Health Sciences Center
2015-present	Core Director: Biostatistics, Epidemiology and Research Design (BERD) of Clinical and Translational Research Infrastructure Network (CTR-IN)	University of New Mexico Health Sciences Center
2014-present	Adjunct Professor, Department of Epidemiology and Biostatistics, and Global Health Sciences	University of California San Francisco
2008-2014	Joint Appointment, UCSF Global Health Sciences, Public Health and Prevention Sciences Group	University of California San Francisco
2006-2014	Joint Appointment, UCSF, Dept. of Medicine; Div. Gastroenterology,	San Francisco Department of Veterans Affairs Medical Center
2006-2008	Secondary appointment, UCSF, Dept. Epidemiology and Biostatistics.	University of California San Francisco
2000-2014	Regional Faculty Coordinator – Latin America and Caribbean Region, UCSF, Center for AIDS Prevention Program International Program,	University of California San Francisco
1998-2014	Secondary appointment, UCSF, Department of Orofacial Sciences, School of Dentistry	University of California San Francisco
1998-1999	Epidemiologist, San Francisco Department of Public Health, HIV Seroepidemiology Unit,	San Francisco Department of Public Health
1995-1996	Post-Doctoral Scholar, Public Health	Municipal Health Department Amsterdam, The Netherlands
1994-1995	Statistician, Department of Epidemiology and Biostatistics	University of California San Francisco
1993-1995	Research Assistant, Department of Epidemiology,	UC Berkeley, School of Public Health
1992-1993	Graduate Student Instructor, Epidemiology,	UC Berkeley, School of Public Health

PROFESSIONAL RECOGNITION, HONORS

- 2012, Mentor of the Year Award, UCSF Clinical and Translational Fellows Program
- 2012, Finalist, NIDA Avant Garde Award Program
- 2009, Finalist, NIDA Avant Garde Award Program
- 1995-1996, Visiting Research Award, Stichting AIDS Research Amsterdam and Stichting Sapharti
- 1994-1996, Warren Winkelstein Award, Outstanding contribution to Epidemiology, University of California Berkeley
- 1993-1994, Pre-doctoral Training Grant, University of California AIDS Task Force
- 1991-1994, Wellness Scholarship, University of California Berkeley
- 1981, Honors Graduate, North Texas State University
- 1997, BA Honors, University of California Santa Barbara

MEMBERSHIPS IN PROFESSIONAL SOCIETIES

- 1995-present, American Public Health Association
- 2000-present, International AIDS Society
- 2010-present, Society for Epidemiologic Research
- 2012-present, Society for Women’s Health Research

OTHER EXTRAMURAL PROFESSIONAL ACTIVITIES

- **Ad-Hoc Journal Referee (papers reviewed in past 5 years)**
 - Addiction (2)
 - AIDS (2)
 - AIDS and Behavior (3)
 - AIDS Research & Human Retrovirus (1)
 - Am Jour Public Health (4)
 - Archives of Virology (1)
 - Biomed Central (2)
 - BMC Infectious Diseases (3)
 - Brazilian Journal of Infectious Disease (3)
 - Clinical Infectious Disease (2)
 - Drug and Alcohol Dependence (6 papers)
 - Expert Reviews in Anti-infective Therapy (1)
 - Gastroenterology (1)
 - Health Psychology (1)
 - Hepatology (3)
 - Int. J. Drug Policy (4)
 - Int. J. STD & AIDS (1)
 - JAMA (1)
 - J Epidemiology & Community Health (1)
 - J Immigrant & Minority Health (1)
 - J Infectious Disease (4)
 - JAIDS (5 papers)
 - J Med Virology (1)
 - J Viral Hepatology (1)
 - PLOS Medicine (3)
 - PLOS One (2)
 - STD (1 paper)
 - Transfusion (1 paper)
 - Vaccine (2 papers)

Service With Professional Organizations

2015	Society for Epidemiologic Research, Epidemiology Conference of the Americas 2016	Reviewer
2015	International AIDS Society, 8 th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Vancouver, CA	Reviewer
2015	Society for Epidemiologic Research 48 th Annual Meeting, Denver, CO, USA	Reviewer
2014	International AIDS Society XX International AIDS Conference, Melbourne, Australia	Reviewer

2013	International AIDS Society, 7 th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia	Reviewer
2012	International AIDS Society XIX International AIDS Conference, Washington D.C., USA	Reviewer
2011	International AIDS Society, 6 th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Rome, Italy	Reviewer
2010	International AIDS Society XVIII International AIDS Conference, Vienna, Austria	Reviewer
2009	International AIDS Society, 5 th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa	Reviewer
2008	International AIDS Society, XVII International AIDS Conference, Mexico City, Mexico	Reviewer
2007	International AIDS Society, 4 th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Sydney, Australia	Planning Committee, Reviewer
2007	International Harm Reduction Society, 18 th International Conference, Warsaw, Poland	International Program Advisory Group
2006	International Harm Reduction Society, 17 th International Conference, Vancouver, Canada	Executive Committee

Government And Other Professional Service

2012-present	National Institutes of Health	CHARTERED MEMBER: ACE Committee
2015	National Institutes of Health	Grant reviewer; Special Emphasis Panel (ZRG1 AARR-F (90) S. Implementation Science in HIV/AIDS Interventions
2015	Center for Drug Use and HIV Research, New York State University	Advisory Panel Member
2015	National Institutes of Health	Grant Reviewer Special Emphasis Panel (ZRG1 AARR-F (90) S. Implementation Science in HIV/AIDS Interventions
2015	Centers for Disease Control and Prevention	Grant Reviewer PAR 14-255 (AARD-55) HIV, HCV, HBV Special Emphasis Panel
2006 to 2014	San Francisco Department of Public Health	SF Chronic Viral Hepatitis Advisory Panel
2012	National Institutes of Health	Grant Reviewer RFA-12-004/005 (ad-hoc)
2011-2012	National Institutes of Health	Grant Reviewer: ACE Review Committee (ad hoc)
2011	San Francisco Dept. of Public Health: Mayor's Task force on Hepatitis C virus infection	Panelist/Presenter
2009	National Institutes of Health	Grant Reviewer: ARRA "Challenge" Grants

2008	National Institutes of Health	Grant Reviewer: BSCH Review Committee (ad-hoc)
2008	National Institutes of Health: DAIDS Funded U.S. Military HIV Research Program (USMHRP) Research Projects.	Reviewer
2008 to present	Center for HIV Law and Policy - Teen SENSE program.	Advisory Committee Member
2007	Centers for Disease Control and Prevention	Grant Reviewer: Two Committees of HIV prevention grants
2007	National Institutes of Health	Grant Reviewer: Special Emphasis Panel
2007	Centers for Disease Control and Prevention	Grant Reviewer
2006	California State Health Services, State Office of AIDS, Symposium on Substance Use, HIV and Public Health in California	Organizing Committee
2006	Steering Committee for HCV Vaccine; National Institutes of Health	Member
2006	San Francisco Dept. of Public Health: Mayor's Task Force on Crystal Methamphetamine Consensus Panel	Panelist

UNIVERSITY SERVICE

University of New Mexico Health Sciences Center

2015	University of New Mexico Health Sciences Center Human Subjects Review Committee	Member
2015	UNM Clinical Translational Science Center	Executive Committee Member
2015	UNM CTSC KL-2 Scholars Program	Search Committee Member
2015	UNM Cancer Center	Member
2015	Biostatistics Open-Rank Faculty Search Committee	Member
2014-present	College of Population Health, Doctor of Philosophy (PhD) in Public Health Sciences Curriculum planning committee	Member

University of California San Francisco

2007-2014	UCSF Committee on Human Research – SFGH IRB	Member
2010-2014	UCSF Liver Center	Member
2011-2014	BIRCWH Women's Health Scholars Program	Advisory Board Member
2011-2014	UCSF Resource Allocation Committee: Clinical HIV/AIDS, Infectious Diseases & Global Review Committee	Grant Reviewer
2013	Faculty Task Force for Women in Epidemiology & Biostatistics	Member

2011-2012	Department of Epidemiology and Biostatistics	Director: Post-Doctoral Program.
2008-2014	Department of Epidemiology and Biostatistics	IT Oversight Committee
2005-2014	UCSF Center for AIDS Research (CFAR)	Mentoring Program
2012	UCSF Internal COI Investigation	Committee Chair
2010	Global Health Sciences Review Committee	Reviewer
2010, 2011	Global Health Sciences Faculty Advisory Council	Member
2008-2009	Global Health Sciences: Graduate Group in Global Health Sciences (GGGHS).	Admissions Committee (UCSF Masters in Global Health Science)
2008	Global Health Sciences: Finance Working Group	Co-chair
2008	Department of Epidemiology and Biostatistics	PhD Program: Curriculum Planning Committee
2008	Office of Human Research Protection “Addressing the Challenges of Human Subjects Research 2008”	UCSF IRB Member Participant
2008	Chancellors Advisory Committee on the Status of Women – Junior Faculty Workshop	Small Group Leader
2007	UCSF Clinical Translational Science Institute (CTSI) Mentor Development Program	Participant
2006	Global Health Sciences, Strategic Planning Group on Multidisciplinary collaboration	Participant
2006	CTSC: The NIH Alphabet Soup of Grants from K to R	Presenting participant
2006	Global Health Sciences, Strategic Planning Group on strengthening academic institutions	Participant
2003-2005	AIDS Research Institute; Executive Committee	Elected Member

Community Service

2005-2014	Cabrillo Unified School District, Cunha Middle School, Half Moon Bay, CA	Annual Science Fair Judge
-----------	--	---------------------------

INVITED PRESENTATIONS

International

2015, “*A hepatitis C vaccine: how do we prove it works*”, 2nd Hepatitis Cure & Eradication Meeting, Vancouver, Canada. November 11, 2015

2015, “*Gender differences in HCV infection: from birth to death*”, 5^o National Congress on HIV and Related Viruses, Salvador, Brazil. August 7, 2015

2015, “*Prevention of HCV infection: reviewing the evidence*”, 5^o National Congress on HIV and Related Viruses, Salvador, Brazil. August 6, 2015.

2015, “*Incentivising female sex workers to reduce ATS use and HIV risk*” (Cambodia Integrated HIV and Drug Prevention Implementation Program), 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Vancouver, Canada. July 23, 2015.

2014, “*Do we still need a hepatitis C vaccine?*” Australasian Viral Hepatitis Conference, Alice Springs

2014, “*Testing a prophylactic HCV vaccine: the needs and realities of a clinical trial in injecting drug users*”, National Canadian Research Training Program on Hepatitis C Annual Meeting

2014, “*Delivering care to PWID: substance use and mental health issues*”, 3rd Canadian Symposium on Hepatitis C Virus

2013, “*Strategies for the prevention of HCV infection among people who use drugs*”, 3rd International Symposium on Hepatitis Care in Substance Users, Munich, Germany

2012, “*That’s right... women are different: sex differences in hepatitis C*”, 8th Australasian Viral Hepatitis Conference, Auckland, New Zealand

2010, “*Catch me if you can*”, III Brazilian Conference of HIV/AIDS and Viral Hepatitis and III Congress North Northeast of Infectious Diseases

2010, “*HCV Acute Infection, Clearance, and Reinfection*”, III Brazilian Conference of HIV/AIDS and Viral Hepatitis and III Congress North Northeast of Infectious Diseases.

2009, “*Acute hepatitis C virus infection: incidence, resolution, , and reinfection*” UCSF Liver Center Symposium, San Francisco, CA (Invited Speaker)

2008, “*Hepatitis C en usuarios de drogas juvenes en San Francisco: el "Proyecto UFO"* (Hepatitis C in young injection drug users in San Francisco: the UFO Study). University of Barcelona, Infectious Diseases Department, School of Medicine. May 14, 2008. (Invited Speaker)

2008, “*HCV in the HIV World*”; VII SIMPAIDS: Symposium on AIDS Research, Itapema, Brazil. October 7-11, 2007. (Invited Speaker)

2006, “*Access to programs and research to prevent HIV and HCV among drug users is constrained by ideology and inattention to science*”. 17th International Harm Reduction Conference, Vancouver, Canada, May 1-4, 2006. (Plenary)

National and Regional

2015, “*Biomedical HIV prevention including pre-exposure prophylaxis and opiate agonist therapy for women who inject drugs: State of research and future directions*”, California Society of Addiction Medicine (CSAM) Annual Conference. October 17, 2015

2015, “*Money for Research*”, UNM Human Research Protection Program Research University. Speaker. September 3, 2015

2015, “*Hepatitis C Epidemiology in New Mexico: the role of injection drug use*”, UNM Cancer Center Population Health Seminar Series. September 2, 2015.

2015, “*Hepatitis C Epidemiology in New Mexico: the role of injection drug use*”, New Mexico Annual HIV & HCV Update Conference. April 30, 2015.

2014, “*Hepatitis C Epidemiology and the development of a prophylactic vaccine*”. Los Alamos National Laboratories. Invited presentation to the Computational Biology group. November, 2014

2013, “*HCV in young adult IDU: what we know that can inform prevention*”, Office of HIV/AIDS and Infectious Disease Policy, Office of the Assistant Secretary for Health; Consultation on hepatitis C virus epidemic and young injection drug users

2012, “*Trends in hepatitis C risk among young adult injectors: an informal needs assessment from across the US*”, UCSF Drug User Research Seminar

2010, “*Catch me if you can: sampling hidden populations*”, American Epidemiological Society. Annual Conference

2008, “*HIV and Hepatitis in young injectors in San Francisco: Research and Service in the UFO Study*”. National Alliance of State and Territorial AIDS Directors, Webinar: HIV and Viral Hepatitis Prevention: Addressing the Needs of Young People Who Inject Drugs; (Invited Speaker)

2008, “*Acute hepatitis C in young injection drug users in San Francisco: the UFO Study*”.

2007, “*Methamphetamine in young IDU in San Francisco*”. San Francisco Dept. of Public Health: Mayor’s Task Force on Crystal Methamphetamine Consensus Panel. San Francisco. (Invited Speaker).

2007, “*HIV and sex work in Southeast Asia*”. Institute for Global Health, Dinner Series (Invited Speaker)

GRAND ROUNDS

2016, “Hepatitis C virus: epidemiology, prevention and treatment update”. Taos-Picuris Pueblo Indian Health Center. Invited co-presenter; January 29, 2016.

2015, “Hepatitis C virus: epidemiology, prevention and treatment update”. Zuni Pueblo Indian Health Service. Invited co-presenter; September 30, 2015.

CONSULTING ACTIVITIES TO NON-ACADEMIC ENTITIES

2007, 2008, 2009, 2010, 2011, 2013: Grant Reviewer for International Courses in Research Design to the Blood Systems Research Institute. PI: Ed Murphy

2012-2015: Infotech SOFT: Consultant on development of data management and computational tool for clinical studies, surveillance studies and outbreak investigations of viral hepatitis.

RESEARCH, TEACHING AND SERVICE INTERESTS

Research

My research is principally focused on epidemiological studies of HIV and hepatitis C virus (HCV) infections in high-risk populations. I lead multidisciplinary translational studies with an aim toward

prevention of these infections and impacting public health. To this end, my work includes prospective observational, implementation and intervention research. I take great pride in the trans-disciplinary nature of the work I lead, which includes a diverse and brilliant group of collaborators including clinicians, social scientists, mathematical modelers, public health specialists, as well as basic scientists in the fields of immunology and virology. My research is focused in high risk groups that experience social stigma, and associated vulnerability, including people who inject drugs, sex workers, incarcerated populations, low income men and women, and men who have sex with men. Community support is essential to the success of my research and I like to work closely with health departments and community based organizations to ensure the public health relevance of my research. I lead and conduct research in New Mexico, the U.S. and internationally.

I lead some of the most significant and successful research on HCV infection in the U.S. and internationally. The prospective observational study known as the UFO Study has produced data on acute HCV as well as other blood borne infections and health outcomes including: incidence and risk factors for HCV seroconversion, HIV, mortality, drug-related overdose, gender-related risk, and trends in drug use, including the now recognized increase in opiate pill use. My work with injectors and HCV were significant in my becoming a co-PI on the only HCV vaccine trial ever conducted and still in progress. I opened the San Francisco clinical trial site for this trial, and a new site in Albuquerque, New Mexico. I am also leading new studies of HCV and HIV in New Mexico in response to emerging epidemics in rural and suburban areas being seen nationwide. I have assembled a large consortium of researchers leading other studies of incident HIV and HCV to form a collaborative with merged data from multiple geographic locations, globally, leading to the largest database on HCV and HIV in injectors globally. The primary site for my HIV research is based in Cambodia, where I am implementing an HIV and drug prevention “implementation science” project in 10 provinces throughout the country. This trial is schedule to complete data collection in November, 2016.

I am laying the groundwork for a program project that will assess the population level impact of evidence-based interventions with the goal of eliminating HCV infection in the state of New Mexico. I have begun collaborations with scientists, clinicians and modelers toward this goal, and obtained funding to begin epidemiological studies. Most recently, I led the formation of a consortium of researchers from eight cities in the U.S. interested in testing patient-centered approaches to HCV treatment in active injection drug users. On September 28th 2015, we were informed that our project was awarded by PCORI. I have a significant leadership role in this project including leading the Albuquerque clinical research site, and the implementation of a Data Coordinating Center for this trial at UNM.

I am tremendously excited about this next phase of research and the environment here, which is creative and dedicated to population health - in New Mexico - to demonstrate this potential.

Teaching and Mentoring

The scientists, clinicians, and students I mentor and teach are diverse, in expertise, range and focus. I began mentoring faculty in 2002 when I became an Associate Professor at University of California. I have been a mentor to residents and research fellows, post-doctoral fellows, PhD and Masters students, pursuing different goals, but ultimately seeking academic success. I have many years of experience teaching undergraduate medical education to second-year medical students, leading classes in research methods to clinicians and students in programs in the U.S. and internationally, as well as seminars in seminars in research design and implementation. I have been a primary mentor for faculty with K-grants, including K01's, and recently a K24, on which I am named as the “Mentoring Mentor”. This path – mentoring junior faculty – was one of the important factors that led me to my position at UNM, where I have the opportunity to provide academic and career direction to fellows, junior, mid-level and senior faculty in the Division of Epidemiology, Biostatistics and Preventive Medicine. I am pleased to participate in the teaching mission at UNM HSC, including with faculty and students. A large part of my role in this leadership position, as Chief of the Division is to support the academic success of a range of students, mentees and

faculty. A good example of my leadership in teaching was the recent submission of a proposal that I coached faculty in our Division in collaboration with faculty in Mathematics and Statistics at UNM to submit for the creation of a “New Mexico Summer Institute in Biostatistics”. I believe that Epidemiology and Biostatistics are a ‘basic science’ of research, and a significant part of the mission of the Division is to promote knowledge and help facilitate the best science possible to promote public and population health. I am honored to be leading the Biostatistics, Epidemiology and Research Design cores for the UNM HSC Clinical and Translational Research Center (CTSC), and the Clinical and Translational Research Infrastructure Network (CTR-IN) of the Mountain West Region.

Service

Throughout my academic career, my service activities have included service to the University, professional organizations including international, national and regional groups, as well as to government agencies including local and national health organizations. At the University level, my most significant commitment has been as a member of the Institutional Review Board (IRB). At the University of California San Francisco, I was a member for 7 years. As I not only valued, but truly enjoyed this commitment, I have joined the UNM HSC IRB as a member. I have participated and continue to contribute to a range academic service work at Departmental and Academic levels, including for curriculum development, search and special committees. With respect to professional organizations, my service has been principally in relation to professional meetings and conference planning, reviewing conference abstracts, planning and scientific advisory capacity. I am active as a journal referee and have reviewed for 26 journals in the past five years. I am active as a speaker, nationally and internationally, especially for my work in hepatitis C prevention where I have had invited plenary and feature presentations at international conferences. In 2013, I was invited to present at a U.S. Health and Human Services meeting on HCV and young injectors. I am active nationally at NIH as a grant reviewer and have been a standing member of the NIH AIDS Clinical Epidemiology (ACE) Study Section since 2012. Service is “citizenship”; being engaged gives one a voice in the system.

Key Words: Infectious disease epidemiology, HIV, hepatitis C virus (HCV), bloodborne infections, sexually transmitted infections, prevention, transmission dynamics, chemoprophylaxis, vaccine research, acute HCV infection, global health, international research, international training, injection drug users, sex workers, vulnerable populations, human subjects research; ethics in international research

SCHOLARLY ACHIEVEMENTS

Peer reviewed publications

1. Raven PB, Jackson AW, **Page K**, Moss RF, Bradley O, Skaggs B. The physiological responses of mild pulmonary impaired subjects while using a demand respirator. *Am Ind Hyg Assoc J.* 1981. April; 42(4): 247-57
2. Raven PB, Moss RF, **Page K**, Garmon R, Skaggs B. Clinical pulmonary function and industrial respirator wear. *Am Ind Hyg Assoc J.* 1981 Dec; 42(12): 897-903
3. Nixon JV, Hallmark H, **Page K**, Raven PR, Mitchel JH. Ventricular performance in human hearts aged 61 to 73 years. *Am J Cardiol* 1985 Dec 1; 56(15): 932-87.
4. **Page-Bodkin** KA, Tappero J, Samuel M, Winkelstein W Jr. Kaposi's Sarcoma and faecal-oral exposure. *Lancet* 1992; 339: 1490 (letter).

5. Lang W, Osmond D, **Page-Bodkin K**, Moss A, Winkelstein W. Population-based estimates of antiretroviral therapy and anti-Pneumocystis prophylaxis in San Francisco: 1991. *J Acquir Immune Defic Syndr.* 1993 Feb; 6(2):191-5.
6. Mandell PJ, Weitz E, Bernstein JI, Lipton MH, Morris J, Bradshaw D, **Page-Bodkin KA**, Mattmiller B. Isokinetic trunk strength and lifting strength measures: differences and similarities between low back injured and non-injured workers. *Spine* 1993; 18 (16): 2491-501.
7. Veugelers PJ, Schechter MT, Tindall B, Moss AR, **Page KA**, Craib KJP, Cooper DA, Coutinho RA, Charlebois E, Winkelstein W Jr., van Griensven GJP. Differences in time from HIV seroconversion to CD4⁺ lymphocytes < 500/ μ l, CD4⁺ lymphocytes < 200/ μ l and AIDS in cohorts of homosexual men. *AIDS* 1993; 7: 1325-29.
8. Osmond DH, Charlesbois E, Sheppard HW, **Page KA**, Winkelstein W Jr, Moss AR, Reingold A. A comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. *Jour Inf Dis* 1993; 167: 66-71.
9. Osmond D, **Page KA**, Wiley J, Garrett K, Sheppard HW, Moss AR, Schragger L, Winkelstein W Jr. Human immunodeficiency virus infection in homosexual/bisexual men, ages 18-29: the San Francisco Young Men's Health Study. *Am J Pub Health* 1994; 84: 1933-37.
10. Veugelers P, Strathdee SA, Tindall B, **Page KA**, Moss AR, Schechter MT, Montaner JSC, van Griensven GJP. Increasing age is associated with faster progression to neoplasms but not opportunistic infections in HIV-infected homosexual men. *AIDS* 1994; 8: 1471-75.
11. Veugelers P, **Page KA**, Tindall B, Schechter MT, Moss AR, Winkelstein W Jr., Cooper DA, Craib KJP, Charlesbois E, Coutinho RA, van Griensven GJP. Determinants of HIV disease progression among homosexual men registered in the Tricontinental Seroconverter Study. *Am J Epidemiology* 1994; 140(8): 747-58.
12. Veugelers P, Strathdee SA, Moss A, **Page KA**, Tindall B, Schechter MT, Coutinho RA, van Griensven GJP. Is the Human Immunodeficiency Virus-related Kaposi's sarcoma epidemic coming to an end: Insights from the Tricontinental Seroconverter Study. *Epidemiology* 1995; 6: 382-86.
13. Strathdee S, Veugelers P, **Page-Shafer KA**, McNulty A, Moss AR, Schechter MT, van Griensven GJP, Coutinho RA. Lack of consistency between five definitions of nonprogression in cohorts of HIV-infected seroconverters. *AIDS* 1996; 10: 959-65.
14. **Page-Shafer KA**, Delorenze GN, Satariano WA, Winkelstein W Jr.. Comorbidity and survival in HIV-infected men in the San Francisco Men's Health Study. *Annals of Epidemiology* 1996; 6: 420-30.
15. Chin D, Osmond DH, **Page-Shafer KA**, Glassroth J, Rosen JM, Reichman LB, Kvale PA, Wallace JM, Poole WK and Pulmonary Complications of HIV infection Study Group. Reliability of anergy skin testing in persons with HIV infection. *Am J Resp and Critical Care Med* 1996; 6: 1982-84.
16. **Page-Shafer KA**, Veugelers PJ, Moss AR, Strathdee S, Kaldor J, van Griensven GJP. Sexual Risk behavior and risk factors for HIV-1 seroconversion in homosexual men participating in the Tricontinental Seroconverter Study, 1982-1994. *Am J Epidemiol* 1997; 146: 531-42.

17. Veugelers PJ, Kaldor JM, Strathdee SA, **Page-Shafer KA**, Schecter MT, Coutinho R, Keet IPM, van Griensven GJP. Incidence and prognostic significance of symptomatic primary human immunodeficiency virus type 1 infection in homosexual men. *J Infectious Dis* 1997; 176: 112-17.
18. Martin JN, Ganem DE, Osmond DH, **Page-Shafer KA**, Macrae D, Kedes D. Sexual transmission and the natural history of human herpes virus 8 infection. *N Engl J Med* 1998; 338: 948-54.
19. van Benthem BHB, Veugelers PJ, Cornelisse PGA, Strathdee SA, Kaldor JM, **Page-Shafer KA**, Coutinho RA, van Griensven GJP. Is AIDS a floating point between HIV seroconversion and death? Insights from the Tricontinental Seroconverter Study. *AIDS* 1998; 12: 1039-45.
20. **Page-Shafer KA**, McFarland W, Wohlfeiler D, K Scheer K, Kohn R, Katz MH. Increasing HIV risk behavior and sexually transmitted disease rates in the interval of improved efficacy of antiretroviral therapy regimens, San Francisco, 1994-1997. *MMWR*, January 29, 1999; 48(3): 45-48.
21. Huang L, Stansell J, Osmond D, Turner J, **Page-Shafer K**, Fulkerson W, Wallace J, Rosen M, Glassroth J, Reichman L, Hopewell P, and the Pulmonary Complications of HIV Infection Study Group. Performance of an algorithm to detect *Pneumocystis carinii* Pneumonia in symptomatic HIV-infected persons. *Chest* 1999; 115: 1025-32.
22. Buchacz K, McFarland W, Hernandez M, Klausner JD, **Page-Shafer K**, Padian N, Molitor F, Ruiz JD, Bolan G, Morrow S, Katz MH for the Young Women's Survey Team; Prevalence and correlates of herpes simplex virus type 2 infection in a population-based survey of young women in low-income neighborhoods of northern California. *STD* 2000; 27(7): 393-400.
23. Ruiz JD, Molitor F, McFarland W, Klausner, **Page-Shafer KA**, Parikh Patel A, Sun RK for the Young Women's Survey Team. Prevalence of HIV infection, sexually transmitted diseases, and hepatitis and related risk behavior in young women living in low-income neighborhoods of northern California. *West. J of Medicine* 2000; 172: 368-73.
24. **Page-Shafer KA**, McFarland W, Kim A, Norton P, Rugg DL, Heitgerd J, Katz M, and the HIV Prevention Indicators Field Workgroup. Evaluating National HIV Prevention Indicators: a case study in San Francisco. *AIDS* 2000; 14: 2015-16.
25. Rugg DL, Heitgerd JL, Cotton D, Broyles S, Freeman A, Lopez-Gomez AM, Oldenburg N, **Page-Shafer KA**, and the HPI Field Collaborative. CDC HIV Prevention Indicators: Monitoring and Evaluating HIV Prevention in the United States. *AIDS* 2000; 14: 2003-13.
26. Martin JN, Amad Z, Cossen C, Lam PK, Kedes DH, **Page-Shafer KA**, Osmond DH, Forghani B. Use of epidemiologically well-defined subjects and existing immunofluorescence assays to calibrate a new enzyme immunoassay for human herpesvirus 8 antibodies. *J Clin Microbiol* 2000 Feb; 38(2): 696-701.
27. Marins JR, **Page-Shafer KA**, Beri de Azevedo Barros M, Hudes ES, Chen S, Hearst N. Seroprevalence and risk factors for HIV infection among incarcerated men in Sorocaba, Brazil. *AIDS and Behavior* 2000; 4(1); 122-28.
28. Moon M, Binson D, **Page-Shafer K**, Diaz R., Correlates of HIV risk in a random sample of street youth in San Francisco; *Journal of the Association of Nurses in AIDS Care* 2001; 12(6): 18-27.

29. Greenwood GL, White EW, **Page-Shafer K**, Bein E, Osmond D, Paul J, Stall R. Correlates of heavy substance use among young gay and bisexual men: the San Francisco Young Men's Health Study. *Drug & Alcohol Dependence* 2001; 61: 105-12.
30. Hahn JA, **Page-Shafer K**, Lum PJ, Ochoa K, Moss AR. Hepatitis C infection and needle exchange use among young injection drug users in San Francisco. *Hepatology* 2001; 34(1): 180-87.
31. Turner J, **Page-Shafer K**, Chin D, Osmond D, Mossar M, Markstein L, Houtsing J, Barnes S, Clemente V, Clayton K, Chesney M, and the Pulmonary Complications of HIV Infection Study Group. Adverse impact of cigarette smoking on dimensions of health-related quality of life in person with HIV infection. *AIDS Patient Care STD* 2001; 15(12): 615-24.
32. Misegades L, **Page-Shafer K**, Halperin D, McFarland W, and the YWS Study Investigators Group. Anal intercourse among young low-income women in California: an overlooked risk factor for HIV? *AIDS* 2001; 15: 534-35.
33. **Page-Shafer K**, Shiboski C, Osmond D, Dilley J, McFarland W, Shiboski S, Klausner J, Balls J, Greenspan D, Greenspan JS. Risk of HIV infection attributable to oral sex among MSM and in the MSM population. *AIDS* 2002; 16(17): 2350-52.
34. Kim A, **Page Shafer K**, Ruiz J, Reyes L, Delgado V, Klausner J, Molitor F, Katz M, McFarland W, and the Young Women's Survey Team. Vulnerability to HIV among women formerly incarcerated and women with incarcerated sexual partners. *AIDS and Behavior* 2002; 6(4): 331-38.
35. **Page-Shafer K**, Hahn JA, Lum P, Ochoa K, Graves A, Moss A. HIV infection among young injection drug users in San Francisco. *JAIDS* 2002; 31: 422-31.
36. Fernyak S, **Page-Shafer K**, Kellogg T, McFarland W, Katz MH; Risk behaviors and HIV incidence among repeat testers at publicly funded HIV testing sites in San Francisco: *JAIDS* 2002. 31(1): 63-70.
37. Hahn JA, **Page-Shafer K**, Lum PJ, Bourgois P, Stein E, Evans J, Busch MP, Tobler LH, Phelps B, Moss AR. Hepatitis C seroconversion among young injection drug users: relationships and risk. *Journal of Infectious Disease* 2002; 186: 1558-64.
38. **Page-Shafer K**, Graves A, Kent C, Balls JE, Zapitz VM, Klausner JD. Increased sensitivity of DNA amplification testing for the detection of pharyngeal gonorrhoea in men who have sex with men. *Clinical Infectious Disease* 2002; 34(2): 173-76.
39. Scheer S, Peterson I, **Page-Shafer KA**, Delgado V, Gleghorn A, Ruiz J, Molitor, F, McFarland W, and the Young Women's Survey Team. Sexual and drug use behavior among women who have sex with both women and men: results of a population-based survey. *Am J Public Health* 2002; 92(7): 1110-12.
40. **Page-Shafer KA**, Klausner J, McFarland W, Cahoun-Young B, Morrow S, Molitor F, Ruiz J. Hepatitis C virus infection in young low income women: the role of sexually transmitted infection as a potential co-factor for infection. *Am J Public Health* 2002; 92(4): 670-76.
41. Shugars DC, Sweet SP, Malamud D, Kazmi SH, **Page-Shafer K**, Challacombe SJ. Saliva and inhibition of HIV-1 infection: molecular mechanisms. *Oral Diseases* 2002; 8(2): 169-175.

42. McCarthy GM, Bednarsh H, Jorge J, Ssali CS, Wangrangsimakul K, **Page-Shafer K**. Transmission of HIV in the dental clinic and elsewhere. *Oral Diseases* 2002; 8(2): 126-135.
43. Scheer S, Parks C, McFarland W, **Page-Shafer K**, Delgado V, Ruiz J, Molitor F, Klausner J. Self reported sexual identity, sexual behaviors and selected health indicators: examples from the population-based Young Women's Survey. *Journal of Lesbian Studies* 2003; 7(1): 69-83.
44. Hammer GP, Kellogg TA, McFarland WC, Wong E, Louie B, Williams I, Dilley J, **Page-Shafer K**, Klausner JD. Low incidence of Hepatitis C virus among sexually active non-injection drug using adults seeking anonymous HIV counseling and testing in San Francisco, 1997-2000. *Sexually Transmitted Diseases* 2003; 30(12): 919-24.
45. Turner KR, McFarland W, Kellogg TA, Wong E, **Page-Shafer K**, Louie B, Dilley J, Kent CK, Klausner J. Incidence and prevalence of herpes simplex virus type 2 infection in persons seeking repeat HIV counseling and testing. *Sexually Transmitted Diseases* 2003 Apr; 30(4): 331-34.
46. Lum PJ, Ochoa K, Hahn J, **Page-Shafer K**, Evans J, Moss AR. Hepatitis B virus immunization among young injection drug users in San Francisco (The UFO Study). *Am J Public Health* 2003; 93(6): 919-23.
47. Alves K, **Page Shafer K**, Caseiro M, Rutherford G, Falcao ME, Sucupira MC, Busch MP, Rawal BD, Diaz RS. Risk factors for incident HIV infection among anonymous testing site clients in Santos, Brazil: 1996-1999. *JAIDS* 2003; 32: 551-59.
48. Evans JL, Hahn JA, **Page-Shafer K**, Lum PJ, Stein ES, Davidson PJ, Moss AR. Gender Differences in Sexual and Injection Risk Behavior Among Active Young Injection Drug Users in San Francisco (the UFO Study) *Journal of Urban Health* 2003; 80(1): 137-146.
49. Buavirat, A, **Page-Shafer K**, van Griensven GJP, Mandel JS, Evans J, Chuaratanaphong J, Chiamwongpat S, Sacks R, Moss A. Risk for HIV in Association with Incarceration among Intravenous Drug Users in Bangkok, Thailand. *British Medical Journal* 2003; 326: 308-12.
50. Kral A, **Page-Shafer K**, Riley E, Gee L, Edlin B, Busch MP, Moss A, McFarland W. Persistent HIV Incidence Among Injection Drug Users in San Francisco During the 1990s: Results of Five Studies. *JAIDS* 2004; 37(5): 1667-669.
51. Herring BL, **Page-Shafer K**, Tobler LH, Delwart EL. Frequent HCV superinfection in injection drug users. *Journal of Infectious Diseases* 2004; 190 (8): 1396-403.
52. Miranda AE, Szwarcwald CL, Peres RL, **Page-Shafer K**. Prevalence and risk factors for Chlamydial infection in a population based sample of female adolescents in Brazil. *Sexually Transmitted Diseases* 2004; 31(9): 542-46.
53. Karlsson RK, Jennes W, **Page-Shafer K**, Nixon DF, Shacklett BL. Poorly soluble peptides can mimic authentic ELISPOT responses. *J of Immunological Methods* 2004; (285): 89-92.
54. Porco TC, Martin JN, **Page-Shafer K**, Charlebois E, Cheng A, Osmond DH. Decline in HIV Infectivity Following the Introduction of Highly Active Antiretroviral Therapy. *AIDS* 2004; 18:81-88.

55. Samnang P, Leng HB, Kim A, Canchola A, Moss A, Mandel JS, **Page-Shafer K**. HIV prevalence and risk factors among fishermen in Sihanouk Ville, Cambodia. *Int Journal of STD & AIDS* 2004; 15:479-483.
56. Cohan, D. L., Kim, A., Ruiz, J., Morrow, S., Reardon, J., Lynch, M., Klausner JD, Molitor F, Allen B, Green-Ajufo B, Ferrero D, Bell Sanford G, **Page-Shafer K**, Delgado V, McFarland W. Health indicators among low income women who report a history of sex work: the population based Northern California Young Women's Survey. *Sex Transm Infect*, 2005; 81(5): 428-433. PMID: PMC1745033.
57. Busch MP, **Page-Shafer, K**. Acute HCV infection: implications for research, diagnosis and treatment. *Clinical Infectious Diseases* 2005; 40: 959-961.
58. Kim AA, Penh Sun L, Chhorvann C, Lindan C, van Griensven GJP, Kilmarx P, Louie JK, Leng HB, Sirivongrangson P, **Page-Shafer K**. High prevalence of HIV and sexually transmitted infections among indirect sex workers in Cambodia. *Sexually Transmitted Diseases* 2005; 32 (12): 745-751.
59. Ochoa KC, Davidson PJ, Evans JE, Hahn JE, **Page-Shafer K**, Moss AR. Heroin Overdose among young injectors in San Francisco. *Drug and Alcohol Dependence*; 2005; 80(3): 297-301.
60. Fox RK, Currie SL, Evans J, Wright TL, Tobler L, Phelps B, Busch ML, **Page-Shafer K**. Hepatitis C virus among prisoners in the California State Correctional System. *Clinical Infectious Diseases* 2005; 41 (2): 177-186.
61. Levy V, **Page-Shafer K**, Evans J, Ruiz J, Morrow S, Reardon J, Lynch M, Raymond HF, Klausner JK, Facer M, Molitor F, Allen B, Ajufo BG, Ferrero DV, Bell-Sanford G, McFarland W for HEYMan Study Team. HIV-related risk among Hispanic immigrant men in a population-based household survey in low-income neighborhoods of Northern California. *Sexually Transmitted Diseases* 2005; 32 (8):487-490.
62. **Page-Shafer K**, Saphonn V, Sun LP, Vun MC, Cooper DA, Kaldor JM. HIV Prevention research in a resource -limited setting: the experience of planning a trial in Cambodia. *Lancet*: 2005; 366, 1499-503.
63. Krawczyk CS, Molitor F, Ruiz J, Facer M, Allen B, Green-Ajufo B, Lynch M, Klausner JD, McFarland W, Bell-Sanford G, Ferrero DV, Morrow S, **Page-Shafer K**, Lemp G. Methamphetamine Use and HIV Risk Behaviors Among Heterosexual Men — Five Northern California Counties, December 2001- November 2003; *MMWR* March 17, 2006; 55(10); 273-277.
64. Telles P, Souto K, **Page-Shafer K**; Long term female condom use among vulnerable populations in Brazil. *AIDS and Behavior*, 2006; 10:S67-S75.
65. Carvalho F, Neiva-Silva, Ramos MC, Evans J, Koller SH, Piccininni CA, **Page-Shafer K**; Sexual and drug use behaviors among children and youth in street circumstances in Porto Alegre, Brazil. *AIDS and Behavior*, 2006; 10: S57-S66.
66. **Page-Shafer K**, Sweet S, Kassaye S, Ssali C. Saliva, breast milk and mucosal fluids in HIV transmission. *Advances in Dental Research* 2006; 19:152-157.
67. Kittikraisak J, Davidson PJ, Hahn JA, Lum PJ, Evans JL, Moss AR, **Page Shafer K**. Incarceration among young injectors in San Francisco: associations with risk for hepatitis C virus infection. *Journal of Substance Use* 2006; 11(4):271-281.

68. Bacon O, Lum P, Hahn JH, Evans J, Davidson PJ, Moss A, **Page-Shafer K**. Commercial sex work and risk factors of HIV infection among drug injecting men who have sex with men in San Francisco. *Sexually Transmitted Diseases* 2006; 33(4):226-234.
69. Bernardin F, Herring B, **Page-Shafer K**, Kuiken C, Delwart E. Absence of HCV viral recombination following superinfection. *J Viral Hepatitis* 2006; 13:532-537.
70. Levy V, Prentiss D, Balmas G, Chen S, Israelski D, Katzenstein D, **Page-Shafer K**. Factors in the delayed HIV presentation of immigrants in northern California: implications for voluntary counseling and testing programs. *J Immigrant and Minority Health* 2007; 9(1): 49-54.
71. Sucupira M, Caseiro M, Alves K, Tescarollo G, Janini L, Sabino E, Castelo A, **Page-Shafer K**, Diaz R; High levels of primary antiretroviral resistance genotypic mutations and B/F recombinants in Santos, Brazil. *AIDS Patient Care and STDs* 2007; 21:116-128.
72. Bernardin F, Stramer S, Rehermann B, **Page-Shafer K**, Cooper S, Bangsberg D, Hahn J, Tobler L, Busch M, Delwart E. High levels of subgenomic HCV plasma RNA in immunosilent infection. *Journal of Virology* 2007; 367(2): 446-456. PMID: PMC2001282
73. **Page-Shafer K**, Hahn JA, Lum PJ. Preventing hepatitis C infection in injection drug users: risk reduction is not enough. Invited editorial. *AIDS* 2007; 21(14): 1967-1969.
74. Hunt P, Brenchley J, Sincalir E, McCune JM, Roland M, **Page-Shafer K**, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG; Relationship between T cell activation and CD4 count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in absence of therapy. *Journal of Infectious Diseases* 2008; 197(1): 126-133. PMID: PM18171295.
75. Lum PJ, Hahn JA, **Page-Shafer K**, Evans J, Davidson PJ, Stein E, Moss AR; Hepatitis B virus infection and immunization status in a new generation of injection drug users in San Francisco. *Journal of Viral Hepatitis* 2008; 15(3) 229-236.
76. **Page-Shafer K**, Pappalardo BL, Tobler LH, Phelps BH, Edlin BR, , Moss AR, Wright T, Wright DJ, Caglioti S, Busch MP; Testing strategy to identify cases of acute hepatitis C virus (HCV) infection and project HCV incidence rates. *Journal of Clinical Microbiology* 2008; 46(2): 449-506. PMID: PMC2238141
77. Hahn J, **Page-Shafer K**, Ford J, Paciorek A, Lum P. Traveling young injection drug users at high risk for acquisition and transmission of viral infections. *Drug Alc Dep* 2008; 93:43-50. PMID: PMC2247437
78. Inglez-Dias A, Hahn J, Lum PJ, Evans J, Davidson P, **Page-Shafer K**. Trends in methamphetamine use in young injection drug users in San Francisco from 1998 to 2004: the UFO Study. *Drug and Alcohol Review* 2008; 27 (3): 286-291.
79. Miranda AE, Figueredo NC, Schmidt R, **Page-Shafer K**. A Population-Based Survey for the Prevalence of HIV, syphilis, hepatitis B and hepatitis C virus infections and associated risk behavior among young women in Vitória, Brazil. *AIDS and Behavior* 2008; 12:S25-31.
80. Sampaio-Sa M, **Page-Shafer K**, Bangsberg DR, Evans J, Dourado ML, Teixeira C, Netto E, Brites C. 100% Adherence Study: Educational workshops versus video sessions to improve adherence among

ARV naïve patients in Salvador, Brazil. *AIDS and Behavior* 2008; 12:S54-62.

81. Fialho M, Messias M, **Page-Shafer K**, Farre L, Schmalb M, Pedral-Sampaio D, Ramos M, Brites C. Prevalence and risk of sexual and bloodborne virus infections in incarcerated youth in Salvador, Brazil: opportunity and obligation for interventions. *AIDS and Behavior* 2008; 12:S17-24.
82. Figueredo NC, **Page-Shafer K**, Pereira FE, Miranda AE. Marcadores sorológicos do vírus da hepatite B em mulheres jovens atendidas pelo Programa de Saúde da Família em Vitória, Estado do Espírito Santo, 2006. (Serological markers for hepatitis B virus in young women attended by the Family Health Program in Vitória, Espírito Santo, 2006). *Revista da Sociedade Brasileira de Medicina Tropical* 2008; 41(6); Nov-Dec.
83. Hahn J, Wylie D, Dill J, Sanchez MS, Lloyd-Smith JO, **Page-Shafer K**, Getz WM. Potential impact of vaccination on the hepatitis C virus epidemic in injection drug users. *Epidemics* 2009; 1 (1); 47-57. PMID: PMC2863120.
84. Cox AL, **Page K**, Bruneau J, Shoukry NH, Lauer GM, Kim AY, Rosen HR, Radziewicz H, Grakoui A, Fierer DS, Branch AD, Kaplan DE, Chang KM. Rare Birds in North America: Acute Hepatitis C Cohorts. *Gastroenterology* 2009; 135(1):26-31. PMID: PMC4143376
85. Evans JL, Hahn JA, Lum PJ, Stein ES, **Page K**. Predictors of injection cessation and relapse in a prospective cohort of young injection drug users in San Francisco, CA (UFO Study). *Drug Alcohol Depend.* 2009 101(3); 152-157. PMID: PMC2692897.
86. Miranda AE, St. Louis M, Figueiredo NC, Milbratz I, **Page K**. Young women and their reproductive health needs in a family practice setting: factors influencing care seeking in Vitoria, Brazil. *Family Practice* 2009; 26(6): 493-500. PMID: PMC2791044.
87. Levy V, Yuan J, Ruiz J, Morrow S, Reardon J, Facer M, Molitor F, Allen B, Ajufo BG, Bell-Sanford G, McFarland W, Raymond HF, Kellogg T, **Page K**, for the HEYMan Study Team. Hepatitis B seroprevalence and risk behaviors among immigrant men in a population-based household survey in low-income neighborhoods in Northern California. *Journal of Immigrant and Minority Health* 2010(6): 828. PMID: PMC2964463.
88. **Page K**, Hahn J, Evans J, Shiboski S, Lum P, Delwart E, Tobler L, Andrews W, Avanesyan L, Cooper S, Busch M. Acute hepatitis C infection in young adult injection drug users: a prospective study of incidence, resolution and reinfection. *Journal of Infectious Diseases* 2009; 200 (8): 1216-1226. PMID: PMC2821203.
89. Tsui JI, Vittinghoff E, Hahn JA, Evans JL, Davidson P, **Page K**. Risk behavior after HCV seroconversion in young injection drug users in San Francisco. *Drug and Alcohol Dependence* 2009; 105(1-2):160-163. PMID: PMC 2849721

2010

90. Sarang A, Rhodes T, Sheon N, **Page K**. Policing drug users in Russia: risk, fear and structural violence. *Substance Use and Misuse* 2010; 45:813-864. PMID: PMC2946846
91. Berini C, Gendler S, Pascuccio S, Eirin ME, McFarland W, **Page K**, Murphy E, Biglione MM. Blood

safety in a public setting of Buenos Aires, Argentina: Prevalence and trends in transfusion- transmitted infections from 2003 to 2005. *Journal of Medical Virology* 2010; 82(5);873-877.

92. Hahn JA, Evans JL, Davidson PJ, Lum PJ, **Page K**. Hepatitis C risk behaviors within partnerships of young injecting drug users. *Addiction* 2010; 105(7):1254-1264. PMID: PMC2907461.
93. Maher L, White B, Hellard M, Madden A, Prins M, Kerr T, **Page K**. Candidate hepatitis C vaccine trials and people who inject drugs: challenges and opportunities. *Vaccine* 2010; (28) 7273-7278. PMID: PMC3567229.
94. Levy V, Evans J, Stein E, Davidson P, Lum P, Hahn J, **Page K**. Are young injection drug users ready and willing to participate in preventive HCV vaccine trials? Data from the UFO cohort in San Francisco. *Vaccine* 2010; 28: 5947-5951. PMID: PMC2936506.

2011

95. Couture MC, Sansothy N, Saphon V, Phal SP, Sichan K, Stein E, Evans J, Maher L, Kaldor K, Vun MC, **Page K**, on behalf of the YWHS Collaborative (J Kaldor, SP Kien, L. Maher, T Nemoto, K Page, J Palefsky, V Saphon, MC Vun). High incidence of HIV and STI among young women engaged in sex work in Phnom Penh, Cambodia. *STD* 2011; (38) 33-39. PMID: PMC3729941.
96. Etcheverry MF, Lum PJ, Evans JL, Sanchez E, DeLazzari E, Mendez-Arancibia E, Sierra E, Gatell JM, **Page K**, Joseph J. HIV vaccine trial willingness among injection drug users and non-injection drug users in two urban centers, Barcelona and San Francisco. *Vaccine* 2011(29) 1991-1996. PMID: PMC3747033.
97. Maher L, Phlong P, Mooney-Somers J, Keo S, Stein E, Couture M, **Page K**, on behalf of the YWHS Collaborative (J Kaldor, SP Kien, L. Maher, T Nemoto, K Page, J Palefsky, V Saphon, MC Vun).. "It makes us dare to do what we did not dare to do before": Amphetamine-type stimulant use and HIV/STI risk behaviour among young female sex workers in Phnom Penh, Cambodia. *International Journal of Drug Policy* 2011; 22: 203-9. PMID: PMC3104095.
98. Asher A, Lum P, **Page K**. Assessing candidacy for acute hepatitis C treatment among active young injection drug users. *Journal of the Association of Nurses in AIDS Care* 2011; e-pub April 14. PMID: PMC3140618.
99. Bahia F, Novais V, Evans J, Le Marchand C, Netto E, **Page K**, Brites C. The impact of HTLV-1 infection on clinical and immunological outcomes in patients infected with HIV-1 and hepatitis C virus. *J Acquir Immune Defic Syndr* 2011; 57:S202-S207. PMID: PMC3747031.
100. Telles P, Hahn J, Delwart E, Edlin B, Martin, J, Lum P, Evans J, Kral A, Busch M, Deeks S, **Page K**. Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco. *BMC Infectious Diseases* 2011; 11(1) 208. PMID: PMC3199778
101. Couture M-C, Evans J, Sansothy N, Stein E, Sichan K, Maher L, **Page K**, on behalf of the YWHS Collaborative (J Kaldor, SP Kien, L. Maher, T Nemoto, K Page, J Palefsky, V Saphon, MC Vun). Correlates of amphetamine-type stimulant use and associations with HIV risks among young women engaged in sex work in Phnom Penh, Cambodia. *Drug and Alcohol Dependence* 2012; 1:120 (1-3) 119-26. E-pub Aug 8, 2011. PMID: PMC3226861

102. Miranda AE, Figueiredo NC, McFarland W, Schmidt R, **Page K**. Predicting Condom Use in Young Women: Demographics, Behaviors, Attitudes and Knowledge in a Population-Based Sample in Brazil. *Int. J. STD and AIDS* 2011; (10) 590-5.
103. Maher L, Mooney-Somers J, Phlong P, Couture M-C, Stein E, Evans J, Cockroft M, Sansothy N, Nemoto T, **Page K**, on behalf of the YWHS Collaborative (J Kaldor, SP Kien, L. Maher, T Nemoto, K Page, J Palefsky, V Saphon, MC Vun). Selling sex in unsafe spaces: Sex work risk environments in Phnom Penh, Cambodia. *Harm Reduction Journal* 2011; 8(1) 30. [PMCID: PMC3339327](#).
- 2012**
104. Evans J, Tsui J, Hahn J, Davidson P, **Page K**. Mortality among young injection drug users in San Francisco: A 10 Year Follow-up of the UFO Study. *American Journal of Epidemiology* 2012; 175(4):302-8. [PMCID: PMC3271816](#).
105. Singh KM, Phung Y, Kohlal MS, Lan B Y-A, Chan S, Suen D, Murad S, Rheault S, Davidson P, Evans J, Singh M, Dohil S, Osorio RW, Wakil AE, **Page K**, Feng S, Cooper SL. KIR Genotypic Diversity Can Track Ancestries in Heterogeneous Populations: A Cautionary Note for Disease Association Studies. *Immunogenetics* 2012;64(2)97-109. [PMCID: PMC4143378](#).
106. Pinho A, Chinaglia M, Lippman SA, Reingold A, Diaz RS, Sucupira C, **Page K**, Díaz J. Prevalence and factors associated with HSV-2 and hepatitis B infections among truck drivers crossing the southern Brazilian border. *Sexually Transmitted Infections*; 2012; 87(7):553-9. [PMCID in progress](#).
107. Vickerman P, Grebely J, Dore GJ, Sacks-Davis R, **Page K**, Hickman M, Hellard M, on behalf of the InC3 Collaborative Group. The more you look, the more you find – Modeling the effects of hepatitis C testing interval on reinfection and clearance among injecting drug users. *J Inf Disease* 2012; 205: 1342-1350. [PMCID: PMC3324399](#)
108. Grebely J, Prins M, Hellard M, Cox AL, Osburn W, Lauer G, **Page K**, Lloyd AR, Dore GJ, on behalf of the InC3 Collaborative Group. Toward a hepatitis vaccine: insight from studies of hepatitis c virus reinfection in injection drug users. *Lancet ID* 2012; 12(5): 408-414. [PMCID: PMC3608418](#).
109. Miranda AE, Figueiredo NC, Pinto VM, **Page K**. Fatores de risco para sífilis em mulheres jovens atendidas pelo Programa de Saude da Familia em Vitoria, Brasil. *Anais Brasileiros Dermatologia* 2012 Jan-Feb;87(1):76-83.
110. Davidson, PJ, **Page, K**. Research participation as work: Comparing the perspectives of researchers and economically marginalized populations. *American Journal of Public Health* 2012; 102(7): 1254-9. [PMCID: PMC3478002](#).
111. Kab V, Evans J, Sansothy N, Stein E, Couture M-C, Maher L, **Page K**, on behalf of the YWHS Collaborative (J Kaldor, SP Kien, L. Maher, T Nemoto, K Page, J Palefsky, V Saphon, MC Vun). Testing for amphetamine-type stimulant (ATS) use to ascertain validity of self-reported ATS use among young female sex workers in Cambodia. *Addiction Science & Clinical Practice* 2012; 7: 11-25. [PMCID: PMC3507647](#).

112. Couture M-C, **Page K**, Stein E, Sansothy N, Sichan K, Kaldor K, Evans J, Maher L, Palefsky J, on

behalf of the YWHS Collaborative (J Kaldor, SP Kien, L. Maher, T Nemoto, K Page, J Palefsky, V Sapphon, MC Vun). Human Papillomavirus infection among young women engaged in sex work in Phnom Penh, Cambodia: prevalence, genotypes and risk factors. *BMC Inf Diseases* 2012; 12:166-80. PMID: PMC3436768.

113. Brown C, Krishnan S, Hursh K, Yu M, Johnson P, **Page K**, Shiboski CH. Dental Disease Prevalence in a Cohort of Methamphetamine and Poly-drug users in an Urban Setting. *J Am Dental Assoc.* 2012; 143: 992-1001. PMID: PMC3722990.
114. White B, Madden A, Hellard M, Kerr T, Prins M, **Page K**, Maher L. Increased hepatitis C vaccine trial literacy following a brief intervention among people who inject drugs in Sydney, Australia (The HITS-c study). *Drug and Alc Review* 2013; 32(4): 419-425. 2: e-pub Nov 1, 2012. PMID: PMC3567229.
115. Asher A, Hahn J, Couture MC, Maher K, **Page K**. People who inject drugs, HIV risk and HIV testing uptake in Sub-Saharan Africa. *JANAC* 2012; e-pub Nov 17, 2012. PMID: PMC3800507.

2013

116. Montgomery M, Fatch R, Evans J, Yu M, Davidson P, **Page K**, Hahn J. Injecting Risk Behavior among Traveling Young Injection Drug Users: Travel Partner and City Characteristics. *Journal of Urban Health* 2013 Jun;90(3):500-15 (e-pub June 29, 2012). PMID: PMC3665972.
117. LeMarchand C, Evans J, **Page K**, Davidson P, Hahn J. Hazardous alcohol consumption among young IDU and its association with high risk injecting behaviors. *Drug and Alcohol Dependence:* 2013; 127(1-3): 143-149. PMID: PMC3762448.
118. Maher L., Mooney-Somers J, Phlong P, Couture MC, Phal S, Bates A, Couture M-C, Stein E, **Page K**, on behalf of the YWHS Collaborative (J Kaldor, SP Kien, L. Maher, T Nemoto, K Page, J Palefsky, V Sapphon, MC Vun). Condom negotiation across different relationship types by young women engaged in sex work in Phnom Penh, Cambodia. *Global Public Health* 2013;8(3): 270-83. PMID: PMC3729959
119. Wang Z, Du J, Zhao M, **Page K**, Xiao Z, Mandel JS. HCV infection is independently associated with depression among methadone maintenance treatment heroin users in China. *Asia-Pacific Psychiatry* 2013; 5(3):191-6. e-pub July 27, 2012. PMID: PMC4513657.
120. Grebely J, Morris M, Rice TM, Bruneau J, Cox AL, Kim AY, McGovern BH, Shoukry NH, Lauer G, Maher L, Lloyd AR, Hellard M, Prins M, Dore GJ and **Page K**, on behalf of the InC3 Study Group. Cohort Profile: The International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC3) Study. *International Journal of Epidemiology* 2013; 42(6):1649-59: (e-pub Nov 30, 2012). PMID: PMC3887561.
121. Etcheverry MF, Evans JL, Sanchez E, Mendez-Arancibia E, Meroño M, Gatell JM, **Page K**, Joseph J. Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials: Project CuenTACONTigo. *Human Vaccines Immunther.* E-pub Jan 4, 2013. PMID: PMC3859767.
122. **Page K**, Osburn W, Evans J, Hahn J, Lum P, Asher A, Delwart E, Tobler L, Cox A, Busch M. Frequent sampling of HCV infection reveals intermittently detectable viremia and reinfection. *Clinical Infectious Diseases* 2013; 56(3): 405-413 (e-pub: Dec 12, 2012). PMID: PMC3540042.

123. Pinto Neto LFS, Barros das Neves L, Ribeiro-Rodrigues R, **Page K**, Miranda AE. Dyslipidemia and fasting glucose impairments among HIV patients three years after the first antiretroviral regimen in an AIDS Brazilian outpatient clinic. *Brazilian Journal of Infectious Diseases* 2013; 17(4): 438-443. (e-pub June 1, 2013).
124. Inglez-Dias A., Bastos FI, **Page K**, Ribeiro JM. Políticas de Redução de Danos no Brasil: Lições aprendidas de um programa em São Francisco, CA. *Ciência & Saúde Coletiva*. 2013: e-pub April 26, 2013.
125. Blatya P, Custer B, Gonzalez T, Birch R, Lopes MI, Ferreira M, Carneiro AB, Sabino E, **Page K**, de Almeida-Neto C. Undisclosed Human Immunodeficiency Virus Risk Factors Identified through a Computer-based Questionnaire Program among Blood Donors in Brazil. *Transfusion* 2013 (e-pub: March 22, 2013). PMID: PMC3708980.
126. Evans J, Couture MC, Stein ES, Sansothy N, Maher L, **Page K**, on behalf of the YWHS Collaborative (J Kaldor, SP Kien, L. Maher, T Nemoto, K Page, J Palefsky, V Saphon, MC Vun). Biomarker validation of recent unprotected sexual intercourse in a prospective study of young women engaged in sex work in Phnom Penh, Cambodia. *STD* 2013; 40(6): 462-469. PMID: PMC3891890.
127. Briceño A, Morris M, Evans J, Raymond HF, **Page K**. Characteristics and health service utilization in two samples of young injection drug users recruited using direct and referral methods in San Francisco, California. *J Alcoholism and Drug Dependence* 2013: 1(5):126 doi:10.4172/2329-6488.1000126.
128. **Page K**, Stein E, , Sansothy N , Evans J, Couture M-C, Sichan K, Cockroft M* Mooney-Somers J, Phlong P, Kaldor J, Maher L, (on behalf of the Young Women's Health Study Collaborative: J Kaldor, SP Kien, L. Maher, K Page, J Palefsky, V Saphonn, MC Vun). Sex work and HIV in Cambodia: trajectories of risk and disease in two cohorts of high risk young women in Phnom Penh, Cambodia. *BMJ Open* 2013: Sept., 11. doi:10.1136/bmjopen-2013-003095. PMID: PMC3773643.
129. Grebely J, Grady B, Hajariadeh B, **Page K**, Dore G. Disease progression during advanced fibrosis: *IL28B* genotype or HCV RNA levels (Letter). *Hepatology* 2013 Dec; 60(6):2127-8. (e-pub August 21). PMID: PMC3918244.
130. Asher AK, Santos G-M, Evans J, Dokubo EK, Lee T-H, Martin JN, Deeks SG, Tobler LH, Busch M, Hunt PW, **Page K**. Human Leukocyte Antigen B*57 Does not fully explain hepatitis C clearance in HIV controllers. *AIDS* 2013; 27(17): 2691-2696. (e-pub August 9, 2013). *Erratum AIDS*: 2014; 28 (4): 619. PMID: PMC4125012
131. **Page K**, Morris M, Hahn J, Prins M. Injection drug use and hepatitis C virus infection in young adults: using research evidence to inform prevention. *CID* 2013; 57 Suppl 2; S32-S38. (e-pub July 24, 2013). PMID: PMC3722077.
132. Kim A, **Page K**. HCV serosorting in people who inject drugs-- sorting out the details. Invited Editorial. *Journal of Infectious Diseases* 2013; 208(12): 1929-1931(e-pub October 16, 2013). PMID: PMC3836470.

2014

133. Dokubo K, Evans J, Winkelman V, Cyrus S, Tobler L, Asher A, Briceno A, **Page K**. Comparison of hepatitis C virus RNA and antibody detection in dried blood spots and plasma specimens. *J Clin Virology*

2014; Apr; 59(4):223-7. (e-pub ahead of print January 27). PMID: PMC4026019.

134. Sapp S, van der Laan M, **Page K**. Targeted estimation of binary variable importance measures with interval-censored outcomes. *Int. J Biostat* 2014; May 1;10(1):77-97 (e-pub ahead of print: March 15, 2014). PMID: PMC4491448.
135. Asher AK, Santos G-M, Evans J, Dokubo EK, Lee T-H, Martin JN, Deeks SG, Tobler LH, Busch M, Hunt PW, **Page K**. Response to: A closer look at hepatitis C clearance in HIV controllers: *AIDS* 2014; May 15; 28(8): 1241-2. PMID: PMC4214212.
136. Callegari FM, Neto LFdSP, Medeiros CJ, Scopel CB, **Page K**, Miranda AE. Syphilis and HIV co-infection in patients attending an AIDS outpatient clinic in Vitoria, Brazil. *AIDS and Behavior* 2014; Suppl 1: 104-109. (e-pub June 4,2013). PMID: PMC3818508.
137. Miranda AE, Pinto VM, McFarland W, **Page K**. HIV infection among young pregnant women in Brazil: prevalence and associated risk factors. *AIDS and Behavior* 2014; Suppl 1: 50-52. (e-pub June 11, 2013). PMID: PMC3818388
138. Ikeda JM, Tellez CAL, Hudes ES , **Page K**, Evans J, Racancoj O, Hearst N. Impact of integrating HIV and TB care and treatment in a regional tuberculosis hospital in rural Guatemala. *AIDS and Behavior* 2014; Suppl 1:32-36. (e-pub August 20, 2013). PMID in progress.
139. Ikeda JM, Shafer JR, Ixcot MLS, **Page K**, Hearst N. Risk of sexually transmitted infection among Mayan women in rural Guatemala whose partners are migrant workers. *AIDS and Behavior* 2014; Suppl 1: 96-103 (e-pub August 21, 2013). PMID in progress.
140. Silveira MPT, Guttier MC, **Page K**, Moreira LB. Randomized controlled trial to evaluate the impact of Pharmaceutical Care on therapeutic success in HIV-infected patients in Southern Brazil. *AIDS and Behavior* 2014; Suppl 1: 75-84. (e-pub August 22, 2013). PMID in progress.
141. Silveira MPT, Guttier MC, Moreira LB, Mirzazadeh A, **Page K**. Predictors of non-adherence to clinical follow up among patients participating in a randomized trial testing a Pharmaceutical Care intervention in HIV-positive adults in Southern Brazil. *AIDS and Behavior* 2014; Suppl 1:85-88. (e-pub August 17, 2013). PMID in progress.
142. Grebely J, **Page K**, Sacks-Davis R, van der Loeff M, Rice TM, Bruneau J, Morris MD, Hajarizadeh B, Amin J, Cox AL, Kim A, McGovern B, Schinkel J, George J, Shoukry N, Laur GM, Maher L, Lloyd A, Hellard M, Dore G, Prins M., on behalf of the InC3 Study Group. The effects of female sex, viral genotype and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. *Hepatology* 2014; 59(1):109120. (e-pub August 2, 2013). PMID PMC3972017.
143. Asher AK, Santos G-M, Evans J, Dokubo EK, Lee T-H, Martin JN, Deeks SG, Tobler LH, Busch M, Hunt PW, **Page K**. Response to: A closer look at hepatitis C clearance in HIV controllers: *AIDS* 2014; May 15; 28(8): 1241-2. PMID: PMC4214212.
144. Sapp S, van der Laan M, **Page K**. Targeted estimation of binary variable importance measures with interval-censored outcomes. *Int. J Biostat* 2014; May 1;10(1):77-97 (e-pub ahead of print: March 15, 2014). PMID: PMC4491448.

145. Tracy D, Hahn JA, Fuller Lewis C, Evans J, Briceño A, Morris M, Lum PJ, **Page K**. Young female IDU are at higher risk of incident HCV than young males: a prospective analysis from the UFO Study Cohort. *BMJ Open* 2014 May 29;4(5):e00498 PMID: PMC24875490.
146. Grebely J, Dore GJ, Kim AY, Lloyd A, Shoukry NH, Prins M, **Page K**. The genetics of spontaneous clearance of hepatitis C virus infection: a complex topic with much to learn. *Hepatology*. E-pub ahead of print April 9, 2014. PMID: PMC4192101.
147. Jain J, Evans J, Briceno A, **Page K**, Hahn J. Comparison of Phosphatidylethanol (PEth) results to measures of self-reported alcohol consumption among young injection drug users. *Alcohol and Alcoholism* 2014 Sep-Oct; 49(5):520-4. (e-pub ahead of print: June 14). PMID: PMC4128670.
148. Hayes B, Briceno A, Asher A, Yu M, Evans J, Hahn JA, **Page K**. Acceptability, views, and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs. *BMC Public Health* 2014; Jun 25; 14(1):645. PMID: PMC4091786.
149. Mirzazadeh A, Grasso M, Johnson K, Briceno A, Navadeh S, McFarland W, **Page K**. Acceptability of global positioning system technology to survey injecting drug users' movements and social interactions: a pilot study from San Francisco, USA. *Technol Health Care* 2014; 22(5):689-700. (e-pub ahead of print: July 2). PMID: PMC4511082.
150. Evans JL, Yu M, Morris, M, **Page K**, Hahn J. Concordance of risk behavior reporting within injecting partnerships of young injection drug users in San Francisco. *Drug and Alcohol Dependence* 2014 Sept 1; 142:239-244 (e-pub July 4, 2014). PMID: PMC4471952.
151. White B, Madden A, Prins M, Hellard M, Dore, GJ, **Page K**, Maher L Assessing the feasibility of hepatitis C virus vaccine trials: Results from the Hepatitis C Incidence and Transmission Study-community (HITS-c) vaccine preparedness study. *Vaccine* 2014; Sept 22; 32(42): 5460-7. PMID: PMC4509604.
152. Hajarizadeh B, Grady B, **Page K**, Kim AY, McGovern BH, Cox AI, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J, on behalf of the InC3 Study Group. Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC3 Study. *J Clin Virology* 2014; Nov;61(3):430-4; (e-pub Sept 8, 2014). PMID: PMC4279031.
153. Morris MD, Evans J, Montgomery M, Yu M, Briceno A, **Page K**, Hahn JA. Intimate injection partnerships are at elevated risk of high-risk injecting: a multi-level longitudinal study of HCV-discordant partnerships in San Francisco, CA. *Plos One* 2014; Oct 6; 9(10):1-11. PMID: PMC4186818.
154. Tsui J, Evans J, Lum PJ, Hahn JA, **Page K**. Opioid agonist therapy is associated with lower incidence of hepatitis C virus infection in young adult persons who inject drugs. *JAMA Internal Medicine* 2014; 174(12): 1974-81. PMID: PMC4491435.
155. Vickerman P, **Page K**, Maher L, Hickman M. Opiate substitution treatment and hepatitis C virus prevention: building an evidence base. Commentary on Nolan et al (2014). *Addiction* 2014; Dec; 109(12): 2060-1. PMID: PMC4520398.

156. Wadhwa P, Evans J, Stein E, Gandhi M, Couture M-C, Sansothy N, Sichan K, Maher L, Kaldor J, **Page K**, on behalf of the Young Women's Health Study Collaborative: (J Kaldor, SP Kien, L. Maher, K Page, J Palefsky, V Saphonn, MC Vun). HPV knowledge, vaccine acceptance, and vaccine series completion among female entertainment and sex workers in Phnom Penh, Cambodia: the Young Women's Health Study. *International Journal of STDs and AIDS* 2015; Oct 26(12):893-902 (Epub 2014 Dec 12). PMID: PMC4506266.
157. Hajarizadeh B, Grady B, **Page K**, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris MD, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Geskus RB, Dore GJ, Grebely J, on behalf of the InC3 Study Group. Factors associated with hepatitis C virus RNA levels during early chronic infection: the InC3 Study. *J Viral Hepatitis* 2015; Sep 22(9): 708-17; (e-pub Jan 8, 2015). PMID: PMC4496327.
158. Hajarizadeh B, Grady B, **Page K**, Geskus RB, Kim AY, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Dore GJ, Grebely J, on behalf of the InC3 Study Group. Patterns of hepatitis C virus RNA levels during acute infection: the InC3 Study. *PlosOne* 2015 Apr 2;10(4) (e-pub April 2, 2015). PMID: PMC4279032.
159. Spelman T, Morris MD, Zang G, Rice T, **Page K**, Maher L, Lloyd A, Grebely J, Dore GJ, Kim AY, Shoukry N, Hellard M, Bruneau J. A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs. *J Epidemiology and Community Health* 2015; Aug; 69(8):745-52; (e-pub March 26, 2015). PMID: PMC4515217.
160. Sacks-Davis R, Grebely J, Dore GJ, Osburn W, Cox AL, Rice TM, Spelman T, Bruneau J, Prins M, Kim AY, McGovern BH, Maher L, Shoukry NH, Schinkel J, Allen TM, Morris M, Hajarizadeh B, Lloyd A, **Page K**, Hellard M. Hepatitis C virus reinfection and spontaneous clearance of reinfection: the InC3 Study. *Jour Inf Dis* 2015; Nov 1; 212(9):1407-19; (e-pub April 15, 2015). PMID: PMC4601911
161. Maher L, Dixon C, Phlong P, Mooney-Somers J, Stein E, **Page K**. Conflicting rights: How the prohibition of human trafficking and sexual exploitation infringes on the right to health of female sex workers in Phnom Penh, Cambodia. *Health and Human Rights* 2015; 17(1) E102-13; (e-pub April 30, 2015). PMID in progress.
162. **Page K**, Tsui J, Maher L, Choopanya K, Vanichseni S, Mock PA, Celum C, Martin M. Biomedical HIV prevention including pre-exposure prophylaxis and opiate agonist therapy for women who inject drugs: State of research and future directions. *JAIDS* 2015 Jun 1; 69 Suppl1: S169-75. PMID: PMC4491435.
163. Iverson J, **Page K**, Madden A, Maher L. HIV, HCV and health-related harms among women who inject drugs: Implications for prevention and treatment. *JAIDS* 2015 Jun 1; 69 Suppl1: S176-81. PMID: PMC4505917.
164. Maher L, **Page K**. Reducing bias in prospective observational studies of drug users: The need for upstream and downstream approaches. *Commentary on Sordo et al. Addiction* 2015; Aug 110(8):1259-61. (e-pub Dec 2014). PMID: PMC4505920.
165. Siddiqui SS, Armenta R, Evans JL, Yu M, Cuevas-Mota J, **Page K**, Davidson P, Garfein RS. Effect of

legal status of pharmacy syringe sales on syringe purchases among persons who inject drugs in San Francisco and San Diego CA. *Int. J Drug Policy* 2015: Nov 26(11):1150-7 (e-pub June 23, 2015). PMID: PMC4581911.

166. Le Marchand C, Bahia F, **Page K**, Brites C. Hepatitis C virus infection and spontaneous clearance in HTLV-1 and HIV co-infected patients in Salvador, Bahia, Brazil. *Brazilian J Inf. Disease* 2015: Sep-Oct; 19(5):486-91. [e-pub August 10, 2015]. PMID: PMC4592833.
167. Dixon TC, Ngak S, Stein E, Carrico A, **Page K**, Maher L. Pharmacology, physiology and performance: Occupational drug use and HIV risk among female entertainment and sex workers in Cambodia. *Harm Reduction Journal* Oct 16;12(1):33. PMID: PMC4608294.
168. El-Diwany, **Page K**, Ray SC, Cox AL, Thomas DL, Balagopal A. Selective retention and release of hepatocyte miRNAs during acute hepatitis C infection in humans. *Journal of Virology* 2015; Sep 89(18):9454-64; (e-pub July 8, 2015). PMID: PMC4542372.
169. Doyle J, Deterding K, Grebeley J, Wedemeyer H, Sacks-Davis R, Spelman T, Mathews G, Rice T, Morris M, McGovern B, Kim A, Bruneau J, Lloyd A, **Page K**, Manns M, Hellard M, Dore G. Response to treatment following recently acquired hepatitis C virus infection in a multi-centre collaborative cohort. *Journal of Viral Hepatology* 2015: Dec 22(12): 1020-32; (e-pub June 22, 2015). PMID: PMC4618180.
170. Morris MD, Bates A, Andrew E, Hahn J, **Page K**, Maher L. More than just someone to inject drugs with: the benefits and risks of primary injection partnerships. *Drug and Alcohol Dependence* 2015: Nov 1;156:275-81. (e-pub Sept 30). PMID: PMC4633359.

2016

171. Carrico AW, Nil E, Sophal C, Stein E, Sokunny M, Yuthea N, Evans JL, Ngak S, Maher L, **Page K**. Adapting Evidence-Based Substance Abuse Interventions for Cambodian Female Entertainment and Sex Workers who use Amphetamine-Type Stimulants. *J Behav Med* 2016: e-pub ahead of print 18 January 2016; PMC: in progress
172. Draughon JE, Carrico AW, Evans JL, Stein ES, Couture M-C, SanSothy N, Maher L, **Page K**, on behalf of the Young Women's Health Study Collaborative. The Impact of violence on HIV risk among women engaged in sex work in Phnom Penh. *Drug Alc Dep* 2016; 161: 161-177. (epub ahead of print 6 February, 2016. doi: 10.1016/j.drugalcdep.2016.01.028.). PMID: PMC4792670
173. Dixon TC, Stein E, Ngak S, Srean C, Maly P, Sokunny M, Carrico A, **Page K**, Maher L. Qualitative research and implementation science: informing the acceptability and implementation of a trial of a conditional cash transfer intervention designed to reduce drug use and HIV risk. *Methodological Innovations Online* 2016: 9:1-10.
174. **Page K**, Mirzazadeh A, Rice TM, Kim AY, Cox AL, Morris MD, Hellard M, Bruneau J, Shoukry NH, Dore GJ, Maher L, Lauer G, Lloyd AR, Prins M, McGovern B on behalf of the InC3 Collaborative. *IFNL4* genotype is associated with jaundice and elevated aminotransferase levels during acute HCV infection: findings from the InC³ Collaborative. *Open Forum Infectious Disease* 2016: epub ahead of print 8 February 2016. doi: 10.1093/ofid/ofw024. PMID: PMC4785397

175. Riley E, Evans J, Hahn J, Briceno A, Lum P, Davidson P, **Page K**. A longitudinal study of multiple drug overdose among young people who inject drugs. *Am J Public Health* 2016; 106(5):915-917. (epub ahead of print 21 March 2016. doi: 10.2105/AJPH.2016.303084). PMID: in process.
176. Asher A, Portillo CJ, Cooper BA, Dawson-Rose C, Vlahov D, **Page K**. Clinician's view of hepatitis C virus treatment candidacy with direct-acting antiviral regimens for people who inject drugs. In press: *Substance use and Misuse*.
177. **Page K**, Stein E, Carrico AW, Evans J, Sokunny M, Nil E, Ngak S, Sophal C, McCulloch C, Maher L. A Cluster randomized stepped-wedge trial to evaluate the effectiveness of a conditional cash transfer with cognitive-behavioral aftercare intervention in reducing risk for HIV among female entertainment and sex workers in Cambodia: The CIPI Study. In press: *BMJ Open*.

Works in Progress: Submitted

178. Asher A, **Page K**, Dawson-Rose C, Portillo C, Vlahov D. HCV Treatment Update: What nurses need to know about treatment regimens, and patient and provider factors impacting treatment outcomes. Under editorial review: *Journal of Clinical Nursing*.
179. Rahimi-Movaghar A, Noroozi A, **Page K**, Mohraz M, McFarland W, Malekzali H, Malekinejad M. Transition to and away from injecting drug use among young drug users in Tehran, Iran: a qualitative study. Under editorial review: *Iranian J Psychiatry and Behavioral Sciences*.
180. Mirzazadeh A, Evans JL, Hahn JA, Jain J, Briceno A, Shiboski S, Lum P, Bentsen C, Davis G, Shriver K, Dimapasoc M, Stone M, Busch MP, **Page K**. HIV incidence in young adults who inject drugs in San Francisco: trends and risks in the 3rd and 4th decade of the HIV epidemic. Under editorial review: *PLOS One*.
181. Silveira M, Silveira CT; Guttier MC, **Page K**, Moreira LB. Long-term immune and virological response in HIV-infected subjects receiving antiretroviral therapy. Under editorial review: *Brazilian Journal of Infectious Disease*.
182. Rodrigo C, Eltahla A, Bull RA, Luciani F, Grebely J, Dore GJ, Applegate T, **Page K**, Bruneau J, Morris MD, Cox AL, Kim AY, Schinkel J, Shoukry NH, Lauer GM, Maher L, Hellard M, Prins, Lloyd A, on behalf of the InC3 Study Group. Phylogenetic analysis of full length, early infection, hepatitis C genomes across nine international cohorts. Under editorial review: *Hepatology*.
183. Tsui JI, Mirzazadeh A, Hahn J, Maher L, Bruneau J, Grebely J, Hellard M, Kim A, Shoukry NH, Dore G, Lauer G, Lloyd A, Page K, on behalf of the InC3 Collaborative. The effects of alcohol on spontaneous clearance of acute hepatitis C virus infection in females versus males. Under editorial review: *Hepatology*.
184. Couture M-C, **Page K**, Sansothy Neth, Stein E, Vun MC, Hahn JA. High prevalence of unhealthy alcohol use and comparison of self-reported alcohol consumption to phosphatidylethanol among women engaged in sex work and their male clients in Cambodia. Under editorial review: *DAD*.
185. Morris MD, Shiboski S, Bruneau J, Maher L, Hahn J, Hellard M, Prins M, Cox AL, Dore G, Dietz P,

Grebely J, Kim A, Lauer G, Lloyd A, Rice T, Shoukry N, **Page K**, on behalf of the InC3 Collaborative. Geographic differences in temporal incidence trends of hepatitis C virus (HCV) infection among people who inject drugs: the InC3 Collaborative. Under editorial review: *PlosOne*.

186. Esmaceli A, Mirzazadeh A, Carter GM, Esmaceli A, Hajarizadeh B, Sacks HS, **Page K**. Higher incidence of HCV in females compared to males who inject drugs: a systematic review and meta-analysis. Under editorial review: *PLOS One*

REPORTS AND REVIEWS

Page-Shafer K. Dried blood spot specimens for use in determining recent HIV-1 infection and HIV-1 incidence surveillance. *European Pharmacotherapy* Spring 2006

Bacon O, Pecoraro ML, Galvão J, **Page-Shafer K**. *Analysis of HIV/AIDS in Brazil*. Report prepared for the Country AIDS Policy Analysis Project under USAID Cooperative Agreement PHN-A-00-01-00001-00. San Francisco, CA: University of California San Francisco, 2004
<<http://ari.ucsf.edu/ARI/policy/countries.htm>>

Page-Shafer K, Currie S, Fox RK, Busch MP, Tobler L, Evans J, Wright T. *Hepatitis C Virus Infection In California Correctional Institutions: Epidemiological, Clinical Policy And Prevention Research*. For the California Youth and Adult Correctional Agency, August 5, 2003

Page-Shafer K, McFarland W, Katz M. *1997 HIV Consensus Report on HIV Seroprevalence and Incidence in San Francisco*. City and County of San Francisco Department of Public Health AIDS Office, Seroepidemiology Unit, September 1997

ABSTRACTS AND CONFERENCE PRESENTATIONS (last 5 years: 2010- 2015)

Duff, Evans JL, Stein ES, **Page K**, Maher L on behalf of the Young Women's Health Study Collaborative (Kaldor J, Kien SP, Maher L, Palefsky J, Page K, Sapphon V, Vun MC). High pregnancy incidence and low contraceptive use among female entertainment and sex workers in Phnom Penh, Cambodia: need for prioritization of sexual and reproductive health services. Submitted to the 21st International AIDS Conference (AIDS 2016); 18-22 July, 2016 in Durban, South Africa.

Page K, Stein ES, Carrico AW, Evans JL, Sokunny M, Nil E, Ngak S, Sophal C, McCulloch C, Maher L. A cluster randomized stepped wedge trial of behavioral interventions targeting amphetamine-type stimulant use and sexual risk among female entertainment and sex workers in Cambodia: design of implementation science protocol. Submitted to NIDA College on Drug Dependence Conference, June 11-16 2016.

Esmaceli AA, Mirzazadeh A, Esmaceli E, Hajarizadeh B, Sacks HS, Maher L, Grebely J, Kim AY, Cox AL, Morris MD, Hellard H, Bruneau J, Shoukry NH, Dore GJ, Lloyd AR, Prins M, and **Page K**, on behalf of the InC3 Collaborative. Higher Hepatitis C Virus Incidence In Females: results from InC3, a multi-cohort study. Accepted for Oral presentation at the 20th International Workshop on HIV Observational Databases (IWHOD), April 7-9, 2016 in Budapest, Hungary.

Le Marchand C, Mirzazadeh A, Shiboski S, Rice T, Morris M, Hahn J, **Page K**, on behalf of the InC3 Collaborative (Julie Bruneau, Andrea Cox, Greg Dore, Jason Grebely, Margaret Hellard, Arthur Kim,

Andrew Lloyd, Lisa Maher, Kimberly Page, Maria Prins, Naglaa Shoukry). Risk of hepatitis C virus infection in people who use drugs who report male-to-male sex. *Presented* to AASLD 66th Meeting, San Francisco, CA. November 2015. (Award for one of 10 best poster presentations).

Esmaeili A, Mirzazadeh A, Esmaeili A, Hajarizadeh B, Carter JM, Sacks H, **Page K**. Female to Male Ratio of Hepatitis C Virus Incidence; A Systematic Review and Meta Analysis. *Presented* to the 4th International Symposium on Hepatitis Care in Substance Users; Sydney, Australia. October 2015.

Mirzazadeh A, Evans J, Hahn H, Shiboski S, Bentsen C, Shriver K, Dimpasoc M, Stone M, Busch MP, **Page K**. HIV incidence is low and stable in Young Adults Who Inject Drugs in San Francisco; UFO Study 2000-2014. *Poster presentation* at the International AIDS Society Conference; Vancouver, Canada; July 20-23, 2015.

Carrico AW, Ean N, Sophal C, Stein E, Muth S, Yuthea N, Evans J, Srean C, Weissman A, Ngak S, Maher L, **Page K**. Conditional Cash Transfer and Cognitive-Behavioral Aftercare Support with Female Entertainment and Sex Workers who use Amphetamine-Type Stimulants in Cambodia. *Oral Presentation* at the 2015 International Conference on Global Health: Prevention and Treatment of Substance Use Disorders and HIV. April 22-24, 2015; Hangzhou, China.

Maher L, Dixon C, Phlong P, Mooney-Somers J, Stein E, **Page K**. Punishment as prevention: Impact of legislative and policy changes designed to prevent human trafficking and sexual exploitation on female sex workers in Phnom Penh, Cambodia. *Oral Presentation* at the 2015 International Conference on Global Health: Prevention and Treatment of Substance Use Disorders and HIV. April 22-24, 2015; Hangzhou, China.

Morris MD, Rice T, Shiboski S Mirzazadeh, Bruneau J, Shoukry N, Cox A, Dore G, Grebely J, Hahn J, Kim A, Lauer G, Lloyd A, Hellard M, Maher L, Prins M, **Page K*** on behalf of the InC3 Study Group. Gender differences in hepatitis C virus (HCV) incident infection among people who inject drugs: the InC3 Study. *Poster presentation* at the International Workshop on HIV Observational Databases (IWHOD), March 26-28, 2015; Catania, Italy. ***Presenting Author**.

Tsui J, Evans J, Lum P, Hahn J, **Page K***. Opioid agonist therapy is associated with lower incidence of hepatitis C virus infection in adult person who inject drugs. *Oral presentation* at The Liver Meeting, AASLD 65th Annual Meeting, Boston Massachusetts, Nov. 7-11, 2014 (Presentation Nov. 10, 2014). Publication no: 171. ***Presenting Author**.

Asher A, Evans J, Hahn J, Briceno A, **Page K**. Behavioral risk changes in young people who inject drugs following rapid HCV testing. *Poster presentation* at The Liver Meeting, AASLD 65th Annual Meeting, Boston Massachusetts, Nov. 7-11, 2014 (Presentation Nov. 11, 2014).

Morris MD, Rice T, Shiboski S, Bruneau J, Cox A, Dore G, Grebely J, Hahn J, Kim A, Lloyd A, Hellard M, Maher L, McBover B, Prins M, **Page K**. Historical and geographical trends in hepatitis (HCV) incident infection among people who inject drugs: the InC3 Study. *Poster presentation* at The Liver Meeting, AASLD 65th Annual Meeting, Boston Massachusetts, Nov. 7-11, 2014 (Presentation Nov 11, 2014). Hepatology: 60, 894A-895A

Hajarizadeh B, Grady B, **Page K**, Geskus RB, Kim Ay, McGovern BH, Cox AL, Rice TM, Sacks-Davis R, Bruneau J, Morris M, Amin J, Schinkel J, Applegate T, Maher L, Hellard M, Lloyd AR, Prins M, Dore GJ,

Grebely J, on behalf of the InC3 Study Group. Patterns of hepatitis C virus RNA levels during acute infection: the InC3 Study. *Oral Presentation* at the HCV 2014 Symposium, Banff, Canada. September 7-11, 2014.

Rutherford G, Brickley D, Sehgal R, McFarland M, **Page K**, Lindan K, Schwarcz S, Mandel J. International Traineeships in AIDS Prevention Studies (ITAPS): 25 years of Capacity Building in HIV Prevention Research. *Poster presentation* at the XX International AIDS 2014 Conference, Melbourne, Australia.

Sacks-Davis R, Grebely J, Osburn W, Dore GJ, Cox AL, Rice TM, Spelman T, Bruneau J, Prins M, Kim AY, McGovern BH, Maher L, Shoukry N, Schinkel J, Morris M, Hajarizadeh B, Lloyd AR, **Page K**, Hellard M; HCV reinfection and spontaneous clearance after spontaneous clearance of primary HCV infection. *Oral presentation* to the Annual Scientific Workshop of Australian Centre for HIV and Hepatitis Virology Research (ACH²). Sydney, Australia. October 2013.

Hajarizadeh B, **Page K**, Kim AY, McGovern BH, Cox AL, Rice T, Sacks-Davis R, Bruneau J, Morris M, Amin J, Grady B, Schinkel J, Maher L, Hellard M, Lloyd AL, Prins M, Grebely J, and Dore G on behalf of the InC³ Study Group. Early HCV RNA dynamics and factors associated with high early HCV RNA level during acute HCV infection. *Oral presentation* to the Annual Scientific Workshop of Australian Centre for HIV and Hepatitis Virology Research (ACH²). Sydney, Australia. October 2013.

Couture M-C, Evans J, Sansothy N, Stein E, Sichan K, Maher L, **Page K**, on behalf of the YWHS Collaborative. Binge Use of Amphetamine-Type Stimulants and Exposure to Violence Among a Cohort of Women Engaged in Sex Work in Cambodia. *Poster presentation* at the Society for Prevention Research Annual Conference; San Francisco, CA, USA., May 29-30, 2013

Page K, Stein E, Sansothy N, Evans J, Couture M-C, Sichan K, Maher L, on behalf of the YWHS Collaborative. HIV, amphetamine-type stimulant (ATS), and alcohol use in Cambodian sex and entertainment workers: results from two prospective cohorts. *Poster presentation* at the Society for Prevention Research Annual Conference; San Francisco, CA, USA, May 29-30, 2013

Stein E, Evans JL, Carrico, Sokunny M, Srean C, Weissman A, Ngak S, Sophal C, Yuthea N, Maher L, **Page K**. A Stepped wedge randomized cluster trial assessing reductions in HIV risk and amphetamine-type stimulant use among women engaged in sex work in Cambodia. *Poster presentation* at 2013 International Conference on Global Health: Prevention and Treatment of Substance use Disorders. Taiwan, Taipei; April 17-19, 2013.

Evans J, Couture MC, Stein ES, Sansothy N, Maher L, **Page K**, on behalf of the YWHS Collaborative. Biomarker validation of recent unprotected sexual intercourse in a prospective study of young women engaged in sex work in Phnom Penh, Cambodia. *Poster presentation* at the 2013 International Conference on Global Health: Prevention and Treatment of Substance use Disorders. Taiwan, Taipei; April 17-19, 2013.

Couture M-C, Evans J, Sansothy N, Stein E, Sichan K, Maher L, **Page K**, on behalf of the YWHS Collaborative. High prevalence of amphetamine-type stimulant use and associations with HIV risks among young women engaged in sex work in Phnom Penh, Cambodia. *Poster presentation* at the 2013 International Conference on Global Health: Prevention and Treatment of Substance use Disorders. Taiwan, Taipei; April 17-19, 2013.

Morris M, Grebley J, Rice T, **Page K**, on behalf of the InC3 Collaboration. Cohort Profile: The International Collaboration on Incident HIV and Hepatitis C in Injecting Cohorts (InC3). 2013 UCSF Liver Center Symposium. *Poster presentation*; San Francisco, CA April 12, 2013.

Briceno A, Evans J, Hayes B, Hahn J, **Page K**. "Acceptability and implications of rapid HCV testing among high risk young injection drug users". *Oral Poster presentation* at 2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care. Washington DC, Nov 26-28, 2012.

Asher AK, Stein E, Cox A, **Page K**. "Preparing for and conducting a successful HCV trial with injection drug users: The VIP Study". *Oral Poster presentation* at the 2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care. Washington DC, Nov 26-28, 2012.

DeCarlo P, Tilsner N, Asher AK, Simpson P, Baxter B, **Page K***. "Young adults at risk for HCV: meeting their needs through a model prevention program". *Oral Poster presentation* at the 2012 National Summit on HIV and Viral Hepatitis Diagnosis, Prevention and Access to Care. Washington DC, Nov 26-28, 2012.
***Presenting Author.**

Grebley J, Dore GJ, Schim van der Loeff M, Rice T, Cox AL, Bruneau J, Kim AY, George J, Maher L, Lloyd AR, Hellard M, **Page K** and Prins M, on behalf of the International Collaboration of Incident HIV and Hepatitis C in Injecting Cohorts (InC³). "Female sex variations in IL28B are independently associated with spontaneous clearance of acute HCV infection." 8th Australasian Viral Hepatitis Conference Auckland, New Zealand, 10-12 September 2012. *Oral Poster presentation*

Yu M, Evans J, Morris MD, **Page K**, Hahn J. Concordance of Risk Behavior Reporting in Injecting Partnerships Between Young Injection Drug Users in San Francisco. *Oral presentation*. APHA Conference. San Francisco, CA; October 2012.

Briceno A, Larios S, Lum P, Evans J, Hahn J, **Page K**. Mental health counseling and diagnoses in young IDU. *Oral presentation*. APHA Annual Conference. San Francisco, CA; October 2012.

Stein E; **Page K**. "High HIV and risk in Cambodian entertainment and sex workers: results from two prospective cohorts" XIX International AIDS Conference (AIDS 2012), Washington, D.C., 22-27 July 2012. *Poster Presentation*.

J. Evans, M.-C. Couture, E. Stein, L. Maher, N. Sansothy, **K. Page**, Young Women's Health Study Collaborative (J. Kaldor, S. Phal, L. Maher, T. Nemoto, K. Page, J. Palefsky). "Biomarker validation of recent unprotected sexual intercourse in a prospective study of young women engaged in sex work in Phnom Penh, Cambodia" XIX International AIDS Conference (AIDS 2012), Washington, D.C., 22-27 July 2012. *Poster Presentation*.

Maher L, **Page K**. "Criminalisation, crackdowns and collateral damage: impact of anti-trafficking laws on HIV risk and prevention among female sex workers in Phnom Penh, Cambodia XIX International AIDS Conference (AIDS 2012), Washington, D.C., 22-27 July 2012. *Poster Presentation*.

Ikeda JM, **Page K**, Hudes E, Barrios R, Lopez CA, Hearst N. "TB and HIV Integration Reduces Mortality among the Indigenous Population in Rural Guatemala." XIX International AIDS Conference (AIDS 2012), Washington, D.C., 22-27 July 2012. *Poster presentation*.

Morris, MD, Evans, J, Yu, M, ; Briceno, A; **Page, K**; Hahn, J. “Risk Profiles of Injecting Partnerships: Correlates of receptive syringe and cooker sharing among a cohort of young injection drug users in San Francisco, CA”. XIX International AIDS Conference (AIDS 2012), Washington, D.C., 22-27 July 2012. Oral presentation.

Page K, de Carlo, P. “The UFO Model: An HCV intervention for young adult IDU.” Oral presentation at the Midwest Viral Hepatitis Conference. Chicago, May 2012.

Asher A, DeCarlo P, Cullen C, Simpson P, Baxter B, **Page K**. “Creating a model prevention and education program for young adult injection drug users (IDU)”. Conference on Overcoming Health Disparities in the Bay Area using HIV/AIDS as a Model. Discovery. Innovation. Effectiveness. San Francisco, May 2012. Poster Presentation.

Page K; Stein E. Biomedical HIV prevention trials and implementation of successful interventions: what impact pregnancy? Oral presentation at the 2012 International Microbicides Conference 15-18 April 2012 Sydney, Australia

Maher L, **Page K**. Criminalisation, crackdowns and collateral damage: Adverse consequences and implications for uptake of biomedical HIV prevention. Oral presentation at the 2012 International Microbicides Conference 15-18 April 2012 Sydney, Australia

Morris MD; Evans J; Asher A; Maher K; **Page K**; McCarthy J. Host Lipid Response to HCV Infection: Changes in Lipid Levels Before, During, and After Acute HCV Infection. EASL: The International Liver Congress, Barcelona Spain. April 2012; Poster presentation.

Winkelman V. Tobler L. Dokubo EK, **Page K**, Cyrus S. Dried Blood Spots Elution Methods for the Detection of Hepatitis C Virus. Accepted for presentation at the American Academic of Blood Banking (AABB) Annual Meeting. San Diego, CA. October 22-25, 2011.

Alice K. Asher, Paula Lum, **Kimberly Page.**; Acute Hepatitis C Treatment Candidacy in Young Injection Drug Users: the UFO Study. Association of Nurses in AIDS Care 2010 Annual Conference; Reno Nevada, November 2010

Telles, PD, **Page, K.**, Fertile outcomes from the crossover between prevention and research among injecting drug users, still not translated into much policy change. Poster presentation: XVIII International AIDS Conference, Vienna, Austria. July, 2010.

Kimberly Page, Bill Osburn, Jennifer Evans, Judith Hahn, Andrea Cox, Michael Busch. Controlling hepatitis c virus (hcv): reinfection and intercalation and clearance of viremia in highly exposed young injectors. Poster presentation at the International Liver Congress 2011 by EASL, Vienna, Berlin March 30-April 3, 2011, and at the UCSF Liver Center Conference (March 10, 2011).

Lia Avanesyan, Ann Erickson, Diana Suen, Irina Rudnik, Yume Phung, **Kimberly Page**, Jennifer Evans, Jody Baron, Stewart L. Cooper. Strength of both innate and adaptive cellular responses determines the outcome of acute HCV infection. Submitted to: American Association of Immunology (AAI) Conference, May 2011, San Francisco, CA.

Davidson P., **Page, K**. Consent and research participation in an epidemiologic study of young injecting drug users. Oral presentation at the 138th APHA Annual Meeting (November 6-10, 2010), Denver, CO.

Lisa Maher, Pisith Phlong, Julie Mooney-Somers, Keo Sichan, Tony Masy, Ellen Stein, Marie-Claude Couture, Neth Sansothy, **Kimberly Page** - on behalf of the Young Women's Health Study Collaborative. "It makes us dare to do what we did not dare to do before": Amphetamine-type stimulant use and HIV/STI risk behavior among young female sex workers in Phnom Penh, Cambodia. Oral Presentation, XVIII International AIDS Conference; Vienna. 18-23 July 2010

Marie-Claude Couture, Neth SanSothy, Ellen S. Stein, Jennifer Evans, Keo Sichan, Lisa Maher, **Kimberly Page** - on behalf of the Young Women's Health Study Collaborative. Amphetamine-type stimulant use increases HIV risk among young women engaged in sex work in Phnom Penh, Cambodia. Oral Presentation, XVIII International AIDS Conference; Vienna. 18-23 July 2010

S. Keo; M. Tony; S.P. Kien; M. Cockroft; **K. Page**; E. Stein; L. Maher; M.-C. Couture. The Cambodian Anti-Trafficking Law: Implications for Community-Based Sex Worker HIV Prevention, Care and Research. Accepted for Poster presentation at the XVIII International AIDS Conference 2010, Vienna Austria. 18-23 July 2010

Neth Sansothy; Keo Sichan; Tony Masy; Ellen Stein; Marie-Claude Couture; **Kimberly Page** - on behalf of the Young Women's Health Study Collaborative. Effect of Amphetamine Type Substance (ATS) Use on the Accessing and Utilization of HIV Clinical Care among young high risk women participating in the Cambodian Young Women's Health Study (YWHS). Accepted for Poster presentation at the XVIII International AIDS Conference 2010, Vienna Austria. 18-23 July 2010

Telles-Dias, P., **Page, K.** Fertile outcomes from the crossover between prevention and research among injecting drug users, still not translated into much policy change. Accepted for Poster presentation at the XVIII International AIDS Conference 2010, Vienna Austria. 18-23 July 2010

J. Grebely, G.J. Dore, M. Schim van der Loeff, A.L. Cox, J. Bruneau, A.Y. Kim, A.R. Lloyd, M. Hellard, **K. Page**, M. Prins, on behalf of the InC3 Collaborative Group. Factors Associated With Spontaneous Clearance During Acute Hepatitis C Virus Infection. International Liver Congress™ 2010 by EASL, Vienna, Austria, April 14-18, 2010.

Evans J, Tsui JI, Davidson PJ, Lum PJ, Hahn JA, **Page K.** Mortality Risk and Predictors Among Young Injection Drug Users in San Francisco (UFO Study). International Harm Reduction Conference, Liverpool, 2010. Poster presentation.

Davidson PJ, Hahn JA, Evans J, Lum PJ, **Page K.** Space, place, and needle access in San Francisco, USA: the UFO Study. International Harm Reduction Conference, Liverpool, 2010. Poster presentation.

Couture MC, Maher L, Sansothy N, Saphon V, Phal SK, Keo S, Stein E, Evans J, Kaldor J, Vun MC, **Page K** Incidence of HIV and Sexually Transmitted Infections among Young Women Sex Workers in Phnom Penh, Cambodia. International Harm Reduction Conference, Liverpool, 2010. Oral Presentation.

Couture MC, Sansothy N, Maher L, Stein E, Evans J, Phal SK, Saphon V, Kaldor J, Vun MC, **Page K** Amphetamine-type substance use, HIV/STI and risk behaviors among young women engaged in sex work in Phnom Penh, Cambodia. International Harm Reduction Conference, Liverpool, 2010. Poster presentation.

Couture MC, Saphonn V, Phal S, Neth SS, Keo S, Stein E, Evans J, Kaldor J, Vun MC, **Page K.** HIV and sexually transmitted infections among young women working in the entertainment/sex industry, in Phnom Penh, Cambodia. Accepted for Poster exhibition at the 2009, 5th International IAS Conference on HIV Pathogenesis, Treatment and Prevention, Capetown, South Africa

CURRENT GRANT AND CONTRACT FUNDING:

ACTIVE

<p>3-R01 DA016017-12 (Principal Investigator) NIH/NIDA <i>Acute HCV infection in young injectors</i> This study includes epidemiological, socio-behavioral, and immunological studies of HCV risk and infection in young adult injectors</p>	<p>9/1/2014-8/31/2019 \$1,253,385 direct/yr 1 \$6,698,242 direct/yrs 1-5</p>
<p>2-R01 DA016017-12 (Co-PI with Dr. Carlos Brites NIH/NIDA Administrative Supplement <i>US-Brazil Biomedical Collaborative Research</i> (Parent grant: Acute HCV infection in young injectors) This study is assessing inflammatory markers of HIV, HCV and HTLV infection and associations with cardiovascular outcomes.</p>	<p>5/15/2015-5/14/2016 \$100,000 direct/yr 1</p>
<p>1R01 DA033672-01 (Co-Principal Investigator) NIH/NIDA <i>Cambodia Integrated HIV and Drug Prevention Implementation Program</i> This is an implementation science study of an intervention aimed at reducing amphetamine type stimulant use and HIV risk in female entertainment and sex workers in Cambodia.</p>	<p>5/15/2012-4/30/2017 \$497,465; direct yr 2 \$1,957,208; direct yr 1-5</p>
<p>1 R01 DA031056-01 (Principal Investigator) NIH/NIDA <i>International Collaborative of prospective studies of incident HIV and HCV in IDU</i> This study merges data from 10 prospective studies of incident HIV and HCV including from the U.S., Australia, Canada, The Netherlands.</p>	<p>5/15/2011-4/30/16 \$355,251 direct/yr 3 \$1,853,999 direct yrs 1-5</p>
<p>Administrative Supplement: 1 R01 DA031056-01 (PI) NIH/NIDA <i>International Collaborative of prospective studies of HIV and Hepatitis in IDU</i> This supplemental study with Dr. Judith Tsui at Univ. Washington will assess gender differences in HCV clearance by opiate and alcohol use.</p>	<p>7/01/2014/30/2015 \$97,582 direct/yr 1</p>
<p>HHSN2662040074C (UCSF NIAID STI-CTG [PI Guidice, L]) NIH/NIAID (Co-Protocol Chair/Principal Investigator) <i>Hepatitis C Vaccine trial: Phase I/ II study of a prophylactic vaccine</i> This study is testing an HCV vaccine in active injectors in Baltimore, San Francisco and Albuquerque.</p>	<p>12/1/2010-11/30/2015 \$2,206,296 direct/yr 1 \$20,596,804 direct yrs 1-4</p>

1 ULTR001449 [Larson, R, PI] Co-Investigator, and Core Director for Biostatistics, Epidemiology and Research Design (BERD)	14/8/2015-31/3/2020 \$3,668,850
U54GM104944 [Langer, R, PI]; Co-Investigator, and Core Director for Research Design, Epidemiology & Biostatistics (CRDEB), NIH/NIGMS Clinical and Translational Research Infrastructure <i>Network IDeA-CTR/Core Research Design Epidemiology & Biostatistics</i> This grant supports building clinical and translational research capacity in the Mountain West Research Consortium.	9/15/2013-06/30/2018 \$3,808,870 direct/yr/1 \$3,971,551 direct/current yr 4 \$20,000,000 direct yrs1-5.
1U18PS004568 (Principal Investigator) CDC: National Center for HIV, Viral Hepatitis, STDs and TB Prevention <i>Epidemiology, Prevention and Treatment of young adult people who inject drugs in non-urban New Mexico.</i> This study will assess prevalence and incidence of HCV and access to HIV prevention and care in young adult injectors in New Mexico.	10/1/2014 – 9/31/2017 \$250,000 direct yr/1 \$750,000 direct yrs 1-3
R-34 DA039333-01 (PI P. Coffin) Role: Co-investigator <i>Hepatitis C Treatment as Prevention pilot study with Ledipasvir-Sofosbuvir among people actively injecting drugs (TaSP-C Pilot)</i> This project will assess adherence to HCV treatment using direct-acting antiviral therapy in active injectors.	07/15/1415-7/31/2018 450,000 direct/yr 1-3
PCORI - HPC-1503-28122 (PI. A. Litwin) <i>Patient-Centered Models of HCV Care for People who Inject Drugs</i> Role: Co-Investigator; PI: Data Coordinating Center	11/01/2015-10/31/2020 \$10,000,000 direct/yr 1-5 UNM sub: \$1,613,941 (yrs1-5)

PENDING

5U19AI088790 (PI. J. Ryan) Bay Area Hepatitis C Cooperative Research Center Role: Co-Investigator	12/01/15-11/30/20 \$ 2,473,739 direct/yr 1-5
1 R01 DA041300-01– (PI D Hartigan-O'Connor) NIH/NIAID The opioid use-associated microbiota and changed responses to vaccines and HIV. Role: Co-Investigator	09/01/2015-08/31/2020 \$481,314.00 direct/yr 1 \$2,449,077.00 direct yr1-5
1U24HD090908-01 (MPI S. Winter, K Page) NIDCH/NIGMS New Mexico Pediatric Clinical Research Data Coordinating Center	9/1/16-8/31/20 \$5,353,899 direct yr 1 \$20,471,453 direct yr 1-4

PREVIOUS AWARDS AND GRANTS

1U54 PS001264-01 (Principal Investigator) CDC: National Center for HIV, Viral Hepatitis, STDs and TB Prevention <i>HCV Prevention and Care Education for young adult injectors</i>	09/01/2008 - 08/31/2013 \$120,071 direct/yr 5 \$500,000 direct/yr 1-5
2 R25 MH64712 (Co-Investigator; PI: G. Rutherford) NIH/NIMH <i>International Traineeships in AIDS Prevention Studies (ITAPS)</i>	1/1/2002-7/31/12 \$241,850 direct/yr 8 \$1,334,603; direct/yr 3-8
2P30 MH62246-11 (Co-Investigator; PI: S. Morin) NIH/NIMH Center for AIDS Prevention Studies Role: Deputy Director for Implementation: Global Response Core	9/1/11-5/30/16 \$183,037 direct/yr 1 \$925,317 direct/Yr 1-5
2 D43 TW05799 (Co-Investigator; PI: G. Rutherford) NIH/Fogarty International International Clinical, Operational and Health Services Research and Training Award	09/22/06-04/30/13 \$183,696 direct/yr 10 \$1,279,258 direct/yr 6-13
1R21DA029473-01 (Co-investigator; PI: M. Malekinejad) NIH/NIDA <i>Crucial transitions among young opioid users in Iran</i>	09/15/10-08/31/12 \$151,362; direct/.yr 1 \$250,000 direct yr 1-2
Pacific Rim Research Program (Principal Investigator) UCSC Center for Global, International and Regional Studies) <i>New Hazards for young women sex workers: effects and crisis arising from implementation of recent anti-trafficking laws in Cambodia</i>	5/2/11-12/30/12 \$30,000 direct/yr 1
NHMRC 630483 (Co-Investigator; PI: L. Maher, UNSW) Australia National Health and Medical Research Council <i>Hepatitis C Vaccine Preparedness Study: investing in infectious disease prevention</i>	1/1/10-12/31/12
UCSF CFAR Resource Allocation Program (PI M Couture) <i>Drug and alcohol abuses, risky sexual behaviors and HIV risk among sex workers and their clients in Preah Sihanouk Province, Cambodia: a pilot study and assessment of prevention opportunities</i> Role: Co-Investigator/Mentor	6/1/2011-5/30/2012
1R01NR010995 - 01A1 (Principal Investigator) NIH/NINR <i>Culture and HIV prevention in high risk young women in Cambodia</i>	01/01/2009-6/30/2012 \$311,633 direct/yr 3 \$981,508 direct/ yr 1-3
NHMRC (PI: G. Dore, UNSW) Australia National Health and Medical Research Council <i>Impact of 1L28B Polymorphisms on control of acute hepatitis C infection</i> Role: Co-Investigator	1/1/2011-12/31/2011

<p>Canadian Institutes of Health Research (CIHR) PI: J. Bruneau – Univ. Montreal <i>International research workshop focused on newly acquired HCV in injection drug users</i> Role: Collaborator</p>	<p>1/1/2010-12/31/2010 C\$19,450 year 1</p>
<p>1 R21 DA025441-01 (Principal Investigator) NIH/NIDA <i>ATS use & HIV among young female sex and entertainment workers in Cambodia</i></p>	<p>07/01/2008-6/31/2009 \$103,481 direct/yr 1</p>
<p>2-R01 DA016017 (Principal Investigator) NIH/NIDA <i>Acute HCV infection in young Injectors</i></p>	<p>7/1/2005-6/30/2009 \$1,736,720 direct/yrs 1-4</p>
<p>R01 DA17476 (P. Lum, PI) NIH/NIDA <i>A randomized trial of vaccine adherence in young injectors</i> Role: Co-Investigator</p>	<p>09/30/2003-06/30/2007 \$806,427 direct/yrs 1-4</p>
<p>06-55415 (Principal Investigator) State of CA, DHS <i>Studying Young Drug-using Population in 5 Northern California Counties</i></p>	<p>7/1/2006-6/30/2009 \$404,274/yrs 1-3</p>
<p>RO1 MH068686 (Co-Investigator; C. Pilcher, PI) NIH/NIMH <i>Targeting acute HIV</i></p>	<p>9/1/2003-6/30/2008 \$326,659 direct/yrs 1-5</p>
<p>R34 AI069962 (Multiple PI: K Page; J. Kaldor) NIH/NIAID <i>Safety and pharmacokinetics of tenofovir and emtricitabine in HIV negative Thai women (preparatory phase)</i></p>	<p>7/01/2006-6/29/2007 \$160,213; direct</p>
<p>U01 AI0154241 (Principal Investigator) NIH/NIAID <i>Phase II/III trial of pharmacological HIV prevention</i></p>	<p>9/15/2003-12/31/2006 \$1,737,330 direct/yrs 1-4</p>
<p>SFDPH (Co-PI) <i>Behavioral Surveillance in San Francisco</i></p>	<p>07/01/2003-6/29/2006 \$37,529; direct/yr 1-3</p>
<p>R01 DA016017 (Principal Investigator) NIH/NIDA <i>Acute HCV infection in young Injectors</i></p>	<p>7/1/2002-6/30/2005 \$614,359 direct/yrs 1-3</p>
<p>R03 DK065113 (Principal Investigator) NIH/NIDDK <i>HCV Infection and Treatment in Parolees: a feasibility study</i></p>	<p>09/01/2003-08/31/2006 \$200,000 direct/yrs 1-3</p>
<p>03-75821 (Principal Investigator) California State Office of AIDS <i>Health Assessment of the Young Man (HEYMan): survey of HIV, hepatitis infections and STD in young low-income men.</i></p>	<p>1/1/2001-6/30/2006 \$390,340 direct/yr 1-3</p>
<p>D43 TW05799 (G. Rutherford, PI) NIH/Fogarty International <i>International Clinical, Operational and Health Services Research and Training Award</i></p>	<p>\$219,110 direct/yr 1 912,523 direct/yr 1-5</p>

Role: Co-Investigator	
R01 DE12911-03 (Principal Investigator) NIH/NIDCR <i>Oral acquisition of HIV infection</i>	4/1/2001 - 3/31/2004 \$1,731,131; direct/yr 1-5
State of California Award (Principal Investigator) <i>Hepatitis C Virus in California Correctional Institutions: Epidemiological, Clinical, Policy and Prevention Research</i>	1/1/2000-12/31/2004 1,655,349; direct/yrs1-3
CAPS Innovative Grant (P. Lum, PI) <i>Evaluating targeted methadone treatment as a strategy for preventing HCV</i> Role: Co-Investigator	12/01/2003-8/30/2004 \$14,323; direct/yr1
CAPS Innovative Grant (Principal Investigator) <i>HIV testers and their partners' willingness to participate in a study involving collection of behavioral and biological data associated with HIV risk in Rio de Janeiro, Brazil</i>	1/1/2000-12/31/2004 \$10,000; direct/yr 1
CFAR (Principal Investigator) Center for AIDS Research, P30 AI27763 Targeted HIV prevention research in Cambodia	8/1/02 - 7/31/03 \$37,796; direct/yr 1
CFAR (Principal Investigator) Center for AIDS Research, P30 AI27763 <i>Novel approaches to preventing HIV acquisition and transmission in high-risk sex workers in Cambodia</i>	10/1/2002 -8/31/2003 \$24,955; direct/yr 1
R01 DA12803 (A. Moss, PI) NIH/NIDA <i>HIV and hepatitis in young injectors: a community study</i> Role: Co-Investigator	9/25/1999 - 8/31/2002 \$2,323,161; direct/yrs 1-3
RO1 MH61180-01 (Supplement Principal Investigator) NIH/NIMH (OAD Supplement) Sexual health intervention among Beer Girls in Cambodia	9/1/2001 - 8/31/2002 \$111,949; direct/yr 1
UCSF REAC (Principal Investigator) <i>HCV among non-injection homeless and marginally housed persons</i>	1999-2000 \$6,960/direct yr 1
UARP (A Moss, PI) <i>HIV infection and needle exchange use in young injectors</i> Role: Co-Investigator	1997-1999 \$577,555/direct yrs1-2
RO1 MH61180-01 (Supplement Principal Investigator) NIH/NIMS (OAR Supplement) Molecular epidemiology of HIV in Santos, Brazil	9/1/1999 – 8/31/2000 \$71,323; direct/yr 1
CDC (Multiple PI: K Page and W. McFarland) <i>HIV Prevention Indicators</i>	1999-2000 \$100,000; direct/yrs 1-2

MENTORING AND TEACHING

Mentoring Of Faculty In Research Or Scholarship

Dates	Name	Position while Mentored	Mentoring Role	Current position
<i>University of New Mexico Health Sciences Center</i>				
2015	Li Luo, Ph.D.	Assistant Research Professor, Division of Epidemiology, Biostatistics and Preventive Medicine	Career and Academic Mentor	Assistant Research Professor, UNM HSC
2015	Cristina Murray-Krezan, MS, Doctoral Candidate	Assistant Research Prof., Epidemiology, Biostatistics & Preventive Medicine	Career and Academic Mentor	Assistant Research Professor, UNM HSC
2015	Fares Quedan, Ph.D.	Assistant Research Professor, Division of Epidemiology, Biostatistics and Preventive Medicine	Career and Academic Advisor	Assistant Research Professor, UNM HSC
2015	Jennifer Hetteima, Ph.D.	Assistant Research Professor, Dept. of Family and Community Medicine	Career and Research Advisor	Assistant Research Professor, UNM HSC
2016	Ludmilla Bakhireva, Ph.D. MD	Associate Professor, School of Pharmacy	Career and Academic Mentor	Associate Professor with Tenur, UNM HSC
<i>University of California San Francisco</i>				
2015	Meghan Morris, Ph.D.,	Assistant Professor, Dept. of Epidemiology & Biostatistics	Career and research mentor; Primary K01 Mentor	Assistant Professor, UCSF, Dept. Epi/Biostat
2014-2015	Varena Saxun, M.D.	GI/Hepatology Fellow, Department of General Internal Medicine, UCSF	Masters in Clinical Research Committee Member and Chair.	GI/Hepatology Fellow, Dept. of General Internal Medicine
2013-2014	Blair Burman, M.D.	GI/Hepatology Fellow, Department of General Internal Medicine, UCSF	Masters in Clinical Research Committee Member and Chair.	Faculty Hepatologist & Gastroenterologist, Virginia Mason Medical Center, Seattle WA
2009-2010	Loris Hwang, M.D	Assistant Professor, Division of Adolescent Medicine, Dept. Pediatrics, UCSF.	Masters in Clinical Research Committee Member and Chair.	Assistant Professor, Division of Adolescent Medicine, Dept. Pediatrics, UCSF.
2007-2008	Judith Tsui, M.D., MPH	Assistant Professor, Internal Medicine, San Francisco Veterans Administration Medical Center	Career and research mentor; K23 Secondary Mentor	Asst. Professor, Internal Medicine, University of Washington
2006-	Paulo Telles,	Faculty, University of Rio	Research Supervision	Visiting Asst. Prof.

2008	MD, PhD	de Janeiro, Brazil & NIH NIDA Postdoctoral Fellow		Epi/Biostat UCSF; Assoc. Professor, Rio de Janeiro State Univ., Brazil
2006- 2007	Brad Aouizerat, PhD	Assistant Professor, Genetics, School of Nursing	Career and Faculty Mentor (CFAR Mentoring Program)	Professor, School of Nursing
2006- 2008	Judith Hahn, PhD	Assistant Adjunct Professor, DoM SFGH Infectious Disease UCSF	Research Supervision; Career Mentor; K01 Primary Mentor	Associate Professor, DoM SFGH Infectious Disease UCSF

Ph.D. Student Mentoring

Dates	Name	Program or School	Role	Current position
2011- 2015	Alice Asher	UCSF School of Nursing	Ph.D Advisory Committee	Ph.D. conferred May 2015.
2004- 2010	Peter Davidson	UCSF; Medical Sociology	PhD Advisory Committee	Assistant Professor, School of Medicine, UCSD
2011	Glen-Milo Santos	UCSF Dept of Epidemiology and Biostatistics	Research Advisor; Ph.D. Epidemiology and Translational Science	Assistant Professor, School of Nursing UCSF

Post-Doctoral Fellows, Medical Students And Residents Supervised Or Mentored

Dates	Name	Fellowship	Faculty Role	Current position
<i>University of New Mexico Health Sciences Center</i>				
2015	Martha Carvour, M.D., PhD	UNM HSC Resident, Infectious Disease	Mentor	UNM HSC Dept of Internal Medicine, Div. of Infectious Disease; 1 st year Resident
2015	Kanwal Qidwai	UNM HSC Resident, Preventive Medicine	Research Mentor	UNM HSC Dept of Internal Medicine, Preventive Medicine; 1 st year Resident
<i>University of California San Francisco</i>				
2011- present	Meghan Morris, Ph.D.	Epidemiology Post- Doctoral Traineeship	Primary Mentor Research Supervision, K01 Mentor	UCSF; Assistant Professor, Dept. of Epidemiology & Biostatistics
2015- present	Chloe LeMarchand, MGH	UCSF Medical Student CTSC 1-year Research Year	Research mentor and supervisor	4 th year Medical Student
2014- present	Jessica Draughon, R.N., Ph.D.	UCSF Post-Doctoral Fellow	Research Mentoring	University of California Davis; Assistant Professor, School of Nursing

2013-2014	Ali Mirzazadeh, M.D., Ph.D.	UCSF Fellow	Research Mentoring	UCSF; Assistant Professor, Epidemiology & Biostatistics; Global Health.
2013-2014	Amy Conroy, Ph.D.,	CFAR Mentoring program	CFAR Mentor	UCSF; Post-Doctoral Fellow CAPS; Dept. of Medicine
2013	Ben Hayes, MPH, MSW	UCSF Medical Student	Research mentoring	UCSF; 4th year Medical Student
2013	Abigail Batchelder, Ph.D.	Post-doctoral Fellow, Psychiatry	Research mentoring	UCSF; Fellow, Psychiatry
2013	Rachel Rutishauser, M.D.	Resident: Internal Medicine	Research Mentoring	UCSF, Department of Internal Medicine, Div. of Infectious Disease. 2 nd year Resident, UCSF
2013	Alex Hernandez, Ph.D.	CFAR Mentoring program	CFAR Mentor	Touro University, Assistant Professor, Public Health Program, Global Health Track.
2011-2012	Sarah Wolfe-King, Ph.D.	CFAR Mentoring program	CFAR Mentor	UCSF; Assistant Professor CAPS; Dept. of Medicine
2010-2011	Mohsen Malikinejad, MD	International Traineeship in AIDS Prevention (ITAPS)	Research and grant development	UCSF; Asst. Professor, Health Policy, Dept. of Medicine.
2009-2011	Emily Kainne Dokubo, MD	Center for AIDS Prevention Studies, Traineeship in AIDS Prevention	Research Supervision	CDC: Epidemic Intelligence Service
2009-2013	Marie-Claude Couture, PhD	Canadian Institutes for Health Research	Primary Mentor and Research Supervision	San Francisco University (SFU); Assistant Professor; School of Nursing

Masters Students

Dates	Name	Program or School	Role	Current position
<i>University of New Mexico Health Sciences Center</i>				
2015-present	Nicholas Karnezis	UNM HSC Masters in Public Health	Research Advisor	UNM MPH student
2014-present	Yuridia Leyva	UNM, Masters in Statistics	Thesis Research Advisor	Biostatistician, UNM HSC
<i>University of California San Francisco</i>				
2013	Shardae Williams	UCSF; Masters in Global Health Science	Capstone Advisor	MGH graduate
2013	Priya Wadhera	UCSF; Masters in Global Health Science	Capstone Advisor	University of Michigan School of Medicine; 1 st

				year Medical Student
2009-2010	Daniel Tracy	Columbia University: Masters in Public Health	Research Advisor; Thesis Reader	MPH Graduate
2009	Chloe LeMarchand	UCSF; Masters in Global Health Science	Capstone Advisor	UCSF; 4 th year Medical Student

FORMAL TEACHING

Undergraduate Medical Education, and Post-graduate Education

Qtr	Academic Years	Course No & Title	Teaching Contribution	Class size
<i>University of California San Francisco School of Medicine</i>				
F	2013	EPI 253; Seminar in Infectious Disease Epidemiology	Course Co-Director, 9 one and one-half hour seminar series.	15
F	2009	GHS201C: Biostatistics, Epidemiology and Clinical Research Design	Course co-Director, 24 one hour lectures; 24 2 hour discussion sessions	18 (First half); 36 (Second half)
F	2006, 2007, 2008, 2010, 2011	I-3; Infection, Inflammation and Immunity; Public Health and International Health	Discussion Group Leader; 3 one hour sessions	20, 20, 20, 13, 16
F	2002, 2003, 2005,	I-3; Infection, Inflammation and Immunity; Public Health and International Health	Discussion Group Leader; 5 one hour sessions	20 each year
F	1999-2003	UCSF Advanced Training in Clinical Research (ATCR) Epidemiologic Methods; Instructor	2 Lectures/year	25 students/session

Other Teaching:

2013	UC Berkeley, School of Public Health: "HCV infection: the need for a vaccine". March 12, 2013 - Epidemiology and Control of Infectious Diseases (PH 253B)
2012	Masters Global Health Science: Illicit drug use and the global HIV epidemic. Feb 24, 2012
2012	Tri-Hospital Conference: Case discussion of HCV/HIV coinfection. Feb 13, 2012.
2009	UC Berkeley, School of Public Health: "Ethical and other challenges of HIV Prevention Trials in Developing Countries," International Health (PH298)
2008	UC San Francisco. "Commercial sex work in Asia" Lecture at Healthcare for the Sex Worker Population February 18, 2009
2008	UC Berkeley, School of Public Health: "Ethical and other challenges of HIV Prevention Trials in Developing Countries," International Health (PH298)
2007	Stanford University. "Ethical and other challenges of HIV Prevention trials in Developing Countries," AIDS Epidemic: Biology, behavior and Global

	Response (399B)
2007	UC San Francisco. “Commercial sex work in Asia” Lecture at Healthcare for the Sex Worker Population February 7, 2007

International Teaching and Education

Qtr	Academic Years	Course Title	Teaching Contribution	Class size
<i>Brazilian Ministry of Health: HIV, STI and Hepatitis Branch</i>				
F	2015	Building capacity for programmatic action for ‘Combination Prevention’ to reduce HIV transmission. [Curso de capacitação para programação de ações de prevenção combinada para a redução da transmissão do HIV]	Course Co-Director	45
<i>FHI360 Cambodia – Classed offered as part of research capacity building</i>				
W	2015	Outbreak Investigation	Class leader	20
Sum	2014	Research Design	Class leader	20

International Research Fellows Mentoring

Dates	Name	Fellowship	Faculty Role	Current position
2012	Marysabel Silveira, Ph.D.	I-TAPS fellow	Research Advising	Asst. Professor, Pharmacology Universidade Federal do Pampa, Uruguiana, Brazil
2012	Paula Blatya, Ph.D.	I-TAPS fellow	Research Advising	Fundacao Pro-Sangue Hemocentro de Sao Paulo. Sao Paulo, Brazil.
2011	Janet Ikeda, MS	I-TAPS fellow	Research Advising	Director, Fundacion IDEI, Guatemala.
2010-2013	Flor Etcheverry, Ph.D.	Doctoral Student (Ph.D. conferred July 2013)	Research Advising	Universidad de Barcelona, Barcelona, Spain
2010	Fabianna Bahia, M.D.	I-TAPS fellow	Research Advising	Research Physician, Infectious Disease Epidemiology, Federal University of Bahia
2008-2011	Anya Sarang, MSc	Fogarty Fellow	Research Supervision	Director, Russian Harm Reduction Network, Moscow, Russia
2006-2012	Carolina Berini, MS	Fogarty Fellow	Research Supervision	Researcher, Centro Nacional de Referencia para el SIDA.

				Dept. of Microbiology, School of Medicine, Universidad de Buenos Aires, Argentina
2005- 2010	Paulo Telles, MD, PhD	Fogarty Fellow	Research Supervision	Faculty, State University of Rio de Janeiro (USRJ), Rio de Janeiro, Brazil

International Traineeships in AIDS Prevention, and International Clinical, Operational, Health Research Training

Qtr	Academic Year	Course No & Title	Teaching Contribution	Class size (average)	Average No. of individual Student Mentees
	2000-2012	Clinical research training in Brazil	Course Leader	10	3
Sum/ Fall	2006 (S, F), 2008, 2010,	Scientific Writing and Dissemination ITAPS @ UCSF	Discussion Group Leader; 5 one hour sessions	10	3
Fall	2004, 2005, 2009, 2010, 2011, 2012	Scientific Writing and Dissemination ICOHRTA @ BRAZIL/UCSF	Didactic sessions with small group interactions; 5 one hour sessions; weekly meetings with each mentee	20	3
Fall	2009, 2013	Epidemiology and Clinical Research Methods @ ITAPS -UCSF	Didactic sessions with small group interactions; 2 one hour sessions per week, and 2 seminar discussion sections per week; weekly meetings with each mentee	16	2
Spring	2011, 2012, 2013	Scientific Writing and Dissemination	Didactic sessions with small group interactions; 2 one hour sessions per week, and 2 seminar discussion sections per week; weekly meetings with each mentee	8	3